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FLAVONOID AND CANNABIDIOL NEURAL GLYOXALASE PATHWAY
ENHANCEMENT AGAINST AGING AND ALZHEIMER’S DISEASE
Joel Frandsen, PhD
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ABSTRACT
Alzheimer’s Disease is a neurodegenerative condition featuring neural cell death
and a decline in cognitive capacity caused by elevated inflammation and production of
reactive oxygen species. The glyoxalase pathway is an endogenous antioxidant system
that neutralizes reactive methylglyoxal through sequential reactions. Dysfunction of the
glyoxalase pathway contributes to oxidative stress and the accumulation of inflammatory
metabolic byproducts. Plant-produced compounds with antioxidant activity can enhance
endogenous antioxidant pathways and protect cells from elevated ROS production. We
hypothesize that flavonoids and limited Cannabis Sativa-produced cannabidiol can
enhance glyoxalase pathway function through regulation of antioxidant and pro-apoptotic
signaling pathways to prevent methylglyoxal-mediated cellular damage. This research
investigates the effects of flavonoids and cannabidiol on glyoxalase pathway function.
We also investigated the influence of structural modifications in flavonoid morin to
improve its inherent antioxidant activity. We evaluated the effect of flavonoids and CBD
on expression of glyoxalase constituents and cell signaling pathways in vitro utilizing
primary mouse cerebellar neurons, and in vivo with C. elegans. Our research provides
evidence of antioxidant compounds enhancing endogenous glyoxalase pathway activity,
and the specific mechanism of cellular signaling pathway modulation.
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INTRODUCTION
The progression of neurodegenerative disorders is heavily influenced by the
cellular microenvironment, where excessive production of reactive oxygen species
(ROS) results in states of oxidative stress (OS) and inflammation.1-8 Elevated ROS is a
contributing factor to the severity and pathology of neurodegenerative disorders, and is a
prominent feature in Alzheimer's disease (AD), Parkinson's disease (PD), Huntington’s
disease (HD), multiple sclerosis (MS), and ischemia. Prolonged states of OS are a
causative and underlying factor in many inflammatory diseases, however it is especially
insidious in neural tissues, where the brain’s high metabolic requirements render the
organ highly vulnerable to damage mediated by excessive concentrations of ROS and
other inflammatory metabolic byproducts.4-7,9-14 OS results from the imbalance between
pro-oxidant and antioxidant compounds, causing a sustained inflammatory response in
cells and tissues.1,6,8,10,14-18 Chronic states of inflammation irreversibly damages cells,
disrupts reduction-oxidation (redox) signaling, prevents integral cellular processes, and
directly impacts and influences the progression and severity of disease.6,13,19 Retention
of endogenous neural antioxidant systems is paramount to proper maintenance and
function of the brain and cognitive processes, which are susceptible to the accumulation
of inflammatory compounds. Ubiquitously produced metabolic byproduct methylglyoxal
(MG) is a dicarbonyl, oxoaldehyde compound and highly reactive glycating agent. 20-26
Due to its highly reactive nature, it is able to spontaneously and irreversibly bind to
proteins, lipids, nucleic acids, metal ions, and other cellular macromolecules forming
advanced glycation endproducts (AGEs).26-29 Compared to their unmodified
counterparts, AGEs have altered chemical structures which prevents their proper
functioning in cellular processes.21,30-34 Accumulation of MG damages cellular
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components through inducement of chronic inflammation and OS.21,24,25,33,35,36 The body
possesses multiple mechanisms to prevent accumulation of carbonyl compounds, but
none are more important or integral in detoxification of MG than the glyoxalase pathway
(GP).1,3,20,21,26,34,37,38
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CHAPTER 1: FLAVONOIDS AS GLYOXALASE
PATHWAY ENHANCING AGENTS
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This chapter will provide information about the function of the GP and its role in aging
and disease, and the mechanism of flavonoid mediated neuroprotection and GP
enhancement. The GP is a well-conserved antioxidant defense system found in all cells
of the body that facilitates the neutralization of highly reactive and oxidizing dicarbonyl
molecules, with MG being the most critical target.3,21,22,37 Through a series of reactions –
involving reduced glutathione (GSH), glyoxalase 1 (Glo-1), and glyoxalase 2 (Glo-2) –
MG is neutralized and detoxified into D-lactate.1,21,22,34,37,39 (A less understood
mechanism of MG detoxification utilizes glyoxalase 3 (Glo-3) to directly convert MG into
D-lactate, which will be examined further in Chapter 4.) Efficient GP function is crucial in
preventing ROS-mediated inflammatory cellular environments, and is implicated in a
wide range of maladies including the previously mentioned neurodegenerative
conditions, psychiatric and neurological disorders, diabetes mellitus, cancer, and
cardiovascular diseases.21,22,27,36,40-44 The brain is susceptible to MG accumulation due to
the high rate of metabolism and low content of antioxidant systems, and is a target for
MG-mediated cellular damage due to the high concentration of oxidizable substrates,
including metal ions, lipids, and polyunsaturated fatty acids.1,21,32,34,37,45-47 GP dysfunction
results in accumulation and decreased neutralization of MG; conversely, accumulation of
MG can be prevented through enhancement of the GP making it a valid target for
pharmacological intervention.22,38,48,49 Increasing the capacity and efficiency of the GP
appears to be an effective means of reducing the onset and severity of aging and
neurodegenerative disease. 22,38,48,49 Pathological hallmarks of these diseases are also
shared in GP dysfunction: production of ROS and inflammatory cytokines, decreased
expression of antioxidant proteins, elevated macromolecule oxidation, and
apoptosis.2,15,17,23,39
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Flavonoids are a class of polyphenol compounds and naturally occurring secondary
plant metabolites, with over 5000 identified compounds possessing a wide range of
biological activity. 50-52 These potent antioxidant compounds exhibit the ability to directly
bind and neutralize ROS and MG, however their primary mechanism of cellular
protection is enhancement of endogenous antioxidant systems - including the GP - and
modulation of anti and pro-apoptotic signaling pathways.53-56 1,37,50,51 Compounds in this
chemical family are currently being investigated as a means to prevent and mitigate OSmediated cellular damage commonly found in neurodegenerative disorders.1,37,54,57-63

Glyoxalase pathway
The GP consists of a series of
sequential reactions involving
GSH, Glo-1, Glo-2, and a
dicarbonyl substrate, often MG
(FIG 1-1).1,21,22,34 MG
FIGURE 1-1: GLYOXALASE PATHWAY SCHEME.

spontaneously reacts with GSH
to form a hemithioacetal, which
is converted by Glo-1 into an
intermediate compound S,D-

Methylglyoxal spontaneously reacts with reduced
glutathione forming a hemithioacetal adduct. Glyoxalase-1
uses hemithioacetal as a substrate to form S,Dlactoylglutathione. Glyoxalase-2 reacts with this intermediate
compound to produce D-lactate, while also reducing
glutathione to be recycled back into the pathway.

lactoylglutathione.1,21,22 Glo-2
participates in the final reaction producing D-lactate and recycling GSH into the pathway.
1,21,22

The GP is a dynamic system able to respond to changes in cellular redox states,

with the rate of glyoxalase activity and expression varying based on the tissue type,
location, and environment of the cell.20,38,64 The GP is ubiquitously present in cells, and
in addition to antioxidant defense it is implicated in cancer cell proliferation, maintenance
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of blood glucose, liver enzymes, and cardiovascular and renal function.3,38 While the
primary function of the GP is antioxidant defense, the D-lactate produced can be
converted to pyruvate and utilized as an energy substrate in the citric acid cycle.1,22,34 In
a functioning glyoxalase system MG is detoxified into D-lactate, however GP dysfunction
results in decreased neutralization and accumulation of MG.3,20,38,64 This can be caused
by a reduction in GP constituent protein expression, dysregulated metabolism, or during
states of disease, resulting in both elevated production of MG and a reduction in its
neutralization.21,24,25,34,64 MG is ubiquitously generated through both enzymatic and nonenzymatic mechanisms.21,22,34 MG is generated through the metabolism of amino acids
glycine, threonine, and tyrosine, protein catabolism, and lipid peroxidation.21,65 Its
primary production occurs through the glycolytic pathway, via elimination of
glyceraldehyde-3-phosphate and dihydroxyacetone phosphate.22,25,65 The glycolytic
pathway is a ten step process of converting glucose into pyruvate, which is then utilized
for ATP production in the citric acid cycle or Krebs cycle.21,32,66 The D-lactate produced
from the GP – also known as the glycolysis shunt - can be directly converted to
pyruvate, thus bypassing glycolysis and providing energy substrates without the
production of inflammatory glycolytic byproducts.22,25,36,66 The GP directly detoxifies
dicarbonyl compound and prevents their interaction with cellular macromolecules, and
has an indirect influence on oxidation levels and metabolic energy production.1,21,22,38,65

7
MG is an electrophile and
highly reactive glycating
agent, able to irreversibly
modify proteins, lipids,
and nucleic acids, forming
advanced glycation
endproducts (AGEs).27,3032,65

These structural
FIGURE 1-2: MG-MEDIATED INFLAMMATION IN DISEASES.

modifications to molecules
can significantly reduce
function, and may lead to
degradation by immune

Elevated production and accumulation of MG contributes to
the underlying inflammatory processes in neurodegenerative
diseases, including disruption of endogenous antioxidant
systems, mitochondrial dysfunction, production of ROS,
AGEs, and cytokines, activation of apoptotic signaling
pathways, and apoptosis.

cells.21,25,30,67 AGEs influence the severity of disease pathology, with the pathological
hallmarks of AD and PD are colocalized to AGEs.30,31,33,35 MG is stable and membranepermeable compound, capable of leaking into surrounding cells and tissues and
impairing the function of cellular antioxidant systems.21 MG is also able to modulate
important signaling pathways, resulting in excessive ROS, inflammation, apoptosis, and
ultimately chronic oxidative stress, leading to death of brain cells, tissues, and
disease.20,33-35,46 ROS can be directly produced during MG’s formation and degradation,
and MG can also deplete the concentration of antioxidant enzymes.23,64 MG can
neutralize enzymes that are able to catalyze reactions and scavenge substrates,
including GSH.23,68-70 MG can also increase NADPH oxidase activity, preventing the
reduction of GSH and its recycling back into the GP.22,23,52,69 GSH is one of the most
important endogenous antioxidants involved in regulation of redox signaling, DNA and
protein repair and synthesis, metal ion metabolism, and cellular survival.68,69,71,72
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The Glyoxalase Pathway in Neural Diseases
The GP exerts control over antioxidant mechanisms that are paramount to maintaining
neural redox homeostasis and preventing the buildup of inflammatory compounds that
drive ROS production.1,21,48,57,58 While the GP is not a direct cause of neurological
disorders, its impaired function can exacerbate the severity of accelerated aging,
neurodegenerative disorders, and neuropsychiatric disorders (Fig. 1-2).3,6,10,16,69
Accumulation of cytotoxic MG directly contributes to the elevated production of ROS,
which drives and sustains apoptotic signaling pathways.3,6,8,10,13,46,73,74 Chronic OS is a
self-perpetuating cycle of damage to cells resulting from the corresponding immune
response, which can be directly linked to elevated concentrations of MG.21-24,32 Under
normal cellular conditions, ROS are utilized in cell signaling and pathogen defense;
during states of disease and metabolic dysfunction their unchecked production disrupts
redox signaling and results in inflammation.2,10,15 ROS and free radicals possess
unpaired electrons and act as nucleophiles to target cellular macromolecules,
irreversibly altering their structures and result in diminished cellular function - similar to
the process of MG-mediated glycation that produces AGEs19,75,76 Structural changes to
proteins, lipids, or nucleic acids reduces the biological activity of macromolecules, and
are often identified as misfolded or damaged and labeled for proteolytic
degradation.21,30,31,38 Lipids are easily oxidizable, and membranes - being rich in lipids are prone to these modifications.10,77,78 MG induces mutations in DNA and nucleic acids,
culminating in telomere shortening, loss of heterochromatin, and altered gene
expression patterns.17,25,79 Metabolic defects and mitochondrial dysfunction can result
from MG-mediated damage involving mitochondrial DNA strand breaks, mutations, and
impaired repair mechanisms.74,79,80 Mouse hippocampal neurons treated with MG
exhibited altered neurogenesis, adversely impacting neural differentiation, survival, and
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proliferation.46 Mice treated with MG exhibited impaired locomotor activity, depressivelike behavior, and deficits in cognition and memory; these abnormalities were correlated
to significantly decreased Glo-1 expression and dopamine levels in the prefrontal
cortex.65 While the specific mechanisms of MG in behavioral and psychiatric disorders
remains to be elucidated, GP dysfunction is also implicated in psychiatric disorders
including ASD, schizophrenia, anxiety, bipolar disorder, and depression.73,81,82

Aging
Aging is a progressive decline in physiological, structural, and metabolic functions of an
organism, and decreased efficiency of homeostatic processes 3,13,15,20 While aging is a
normal biological process, the presence of disease can exacerbate and accelerate the
rate of aging.15,83 The aging process is characterized by chronic, low-level inflammation
which can be influenced by genetic, environmental, and pathological
factors.3,13,15,20,48,64,74,84-86 In the brain, accumulation of genetic and cellular damage
occurs throughout the lifespan, resulting in functional losses in cognitive processes.15,83
Proper and efficient functioning of endogenous antioxidant systems can reduce the
severity of inflammatory processes that contribute to premature and pathological
aging.7,19,74 The GP exhibits dynamic activity in response to aging-related inflammatory
insults, with glyoxalase activity differentially expressed based on age, cell type, and
disease state.64,86,87 Damage mediated by oxidation and glycation of cellular molecules
steadily increases throughout aging, with a concomitant increase in the adaptive
processes that offset inflammatory damage.3,26,86 Glyoxalase activity increases during
aging, however a progressive decline in Glo-1 expression occurs after age 55.64,86
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This age-related reduction in GP efficiency results in production of dicarbonyl
compounds, accumulation of AGEs, and elevated biomarkers of oxidative and
inflammatory damage.26,64,86,87

Alzheimer's Disease
AD is the most common neurodegenerative disorder, and the leading cause of dementia
in the elderly, and places a significant financial burden on the healthcare system.6,88-90
While the underlying genetic causes for familial AD have been determined, over 90% of
AD cases are classified as late onset or sporadic with no known cause for onset.88-91 It is
a multifactorial disease characterized by progressive neural loss of the hippocampus
and cortex, memory and learning impairment, and changes in behavior and personality,
exhibiting pathogenic hallmarks of beta amyloid (Aβ) plaques, neurofibrillary tangles
(NFT), and loss of brain volume.6,89,90,92 Cognitive impairment reflects synapse loss in
dentate gyrus of hippocampus, and neuron loss in frontal and parietal lobe of
cortex.6,12,93-95 The amyloid precursor protein (APP) is a membrane protein involved in
neural plasticity, synapse formation and repair, and export of metal ions.88,89,93,96 The
APP present in the brain can be cleaved by three different secretases: cleavage of APP
first by a-secretase and then g-secretase results in a functional protein; while cleavage
by b-secretase results in insoluble Aβ peptides.89,93,95 The product formed from this
improper cleavage will aggregate into extracellular plaques, disrupt neural function,
induce ROS production, and trigger apoptotic pathways.6,12,93,95 Aβ plaques can be
modified by MG and AGEs, forming crosslinks, affording them stability and defense
against protease cleavage.35,95 The Aβ plaques activate microglia, causing them to
cluster and localize around the plaques, and release inflammatory cytokines.77,95 The Aβ
plaques cause additional production of AGEs, which reduce the activity of mitochondrial
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enzymes and proteins causing increased production of ROS and improper APP
cleavage.21,30-32,35 Age is the biggest risk factor for development of AD, and is correlated
with an increase in ROS formation, oxidized proteins and lipids, and apoptosis.6,12,13
Impairment of the GP can directly impact the severity of AD, with Glo-1 and GSH
expression inversely correlated to severity of disease pathology.26,86,87 In a comparison
of glyoxalase activity between healthy and AD brain tissue, the AD group had a
significantly lowered Glo-1 activity and expression, at both the mRNA and protein
level.26,86,87 Tissue from AD brains exhibits high amounts of AGEs and oxidized lipids
and proteins, with a positive relationship between MG and AGEs and severity of
pathology.31,97 Microtubule associated protein tau is responsible for promoting and
stabilizing microtubule formation in cells, however hyperphosphorylation of tau
destabilizes and disrupts the proper assembly of microtubules, resulting in intracellular
NFT formation.94,98,99 MG can also disrupt cell signaling pathways that control kinases
and phosphatases used to regulate phosphorylation of tau.33,88,97 MG derived AGEs
aggregate in NFT and Aβ plaques, and Aβ plaques have an influential and contributing
role in the production of NFT, and they are both stable molecules prone to
glycation.30,31,35,38 MG concentration can act as a biomarker of severity of disease, as AD
patients were found to have increased MG in CSF compared to healthy aged controls.26

Parkinson's Disease
The second most common neurodegenerative disease, PD, is characterized by
degeneration of dopamine producing neurons in the substantia nigra and deregulation in
ganglion cell circuits, reducing dopamine levels in brain areas associated with
movement.5,14,79,100 The disease is characterized by motor deficiencies - including
tremors, rigidity, and slowness of movement – pathological accumulation of a-synuclein
(aS) into Lewy bodies, and cognitive deficiencies.4,84,100 aS is a protein located in
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presynaptic terminals of neurons that functions in recycling and storage of
neurotransmitters.5,101 Under conditions of inflammation and OS, aS proteins misfold and
accumulate into aggregates which oligomerize into Lewy bodies; these aggregates are
cytotoxic, disrupt connections between neurons, and deplete levels of
neurotransmitters.4,11,14,79 Accumulation of aS and Lewy bodies have a detrimental
impact on mitochondria activity, causing an elevation of ROS production and deficit in
metabolic activity. The degeneration of dopaminergic neurons and oxidation of
dopamine causes altered mitochondrial respiration, inducing a state of OS in neural
tissue.47,79,101,102 aS also reacts with dopamine quinones leading to accumulation of toxic
fibrils in the dopaminergic neurons, which have impaired activity and contribute to
degeneration.12,14,47,84 MG accumulation can lead to elevated production of ROS,
oxidation of dopamine, and depletion of NADPH, which is critical for reducing glutathione
for use in the GP.5,17,71,84 Patients with PD have been found to have depleted levels of
GSH, and disruption of GSH metabolism has been found to progress neurological
disorders.11,69,71,84,102 The decline in synthesis of dopamine also causes disruption in
vesicle transport, and makes the cell prone to damage and mtDNA mutations.78,102,103
There is a correlation between progression of disease and biomarkers of oxidative
stress, and post-mortem studies of PD brains show high levels of oxidized substrates,
and colocalization of AGEs to Lewy bodies.7,14,17,79 AD and PD have different clinical
pathologies but share similar causes and symptoms and Aβ plaques can be commonly
found in PD brains.12,13

Autism Spectrum Disorder
ASD is a multifactorial neurodevelopmental disorder categorized by impairment in
communication, language, social behaviors and relationships.104-107 The basis for the
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disease is still misunderstood, but it is known that mutations in over 100 genes can
contribute to ASD, with the presence of genetic mutations in specific brain regions can
affect emotional formation, learning and memory, cognitive control, and social
orientation.39,73,81,104,106,108,109 ASD exhibits mitochondria-mediated metabolic dysfunction
and physical abnormalities and alterations in brain tissue.109-112 DNA and mtDNA
mutations and abnormalities are common in ASD, resulting in electron transport chain
(ETC) dysfunction, low ratios of Bcl-2/Bak, elevated production of ROS, increased
apoptosis, impairments in mitochondria membrane polarization, molecular transport, and
protein translocation.81,105,109,111-113 ASD is characterized by elevated OS and abnormal,
chronic immune activation of microglia and astroglia which exert negative effects on the
production of neurotransmitters, inflammatory cytokines, and brain specific growth
factors.73,81,110,111 Elevated levels of MG disrupted the function of GABA-producing
Purkinje neurons through elevated production of ROS, high concentrations of AGEs,
lipid peroxidation, and apoptosis, resulting in a disruption of the balance of inhibitory and
excitatory neurotransmission.39,43,104-106,110,114 Elevated MG concentrations in ASD brains
was inversely correlated to levels of GSH; while it’s unknown whether GSH deficits were
due to reduced synthesis or regeneration, MG-mediated signaling pathway activation
was determined to be the culprit.43,69,72,104,108,114,115 The environment of OS present in
ASD is driven in part by MG production, which could be alleviated and attenuated in a
GP dependent manner.1,39,43,69,104,108
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Flavonoid Function

FIGURE 1-3: ANTIOXIDANT FUNCTION OF FLAVONOIDS.
Flavonols possess antioxidant and anti-inflammatory functions mediated through
antioxidant action and modulation of cell signaling pathways.

Flavonoids belong to a family of polyphenol compounds and are secondary plant
metabolites commonly found in fruits and vegetables, and have been found effective in
combating elevated production of ROS.1,51,116 Antioxidants are compounds - when
present at a lower concentration compared oxidizable substrate - that delay or prevent
oxidation of the substrate by acting as nucleophiles to prevent interaction with other
molecules.1,19,51,75,76,117 Endogenous antioxidants produced by the body function in
prevention and neutralization of ROS and free radicals, repair of damaged
macromolecules, and redox signaling; exogenous antioxidants consumed through food
and drink also play an important role in cellular defense and survival, and have shown to
aid the body in combating OS and inflammation.15,19,51,55,75,76 Classes of flavonoids are
distinguished by the presence of multiple phenol rings, C=C double bonds, and hydroxyl
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groups.1,37,118-120 These structural characteristics confer the antioxidant function of
flavonoids, and the number and location of hydroxyl groups influence the biological
activity of the flavonoids, and lipophilicity is also influenced by structure, which allows
some flavonoids to favorably pass through the blood brain barrier.1,37,50,51,119-121 This
class of antioxidant molecules possesses several distinct mechanisms of protection from
OS: flavonoids can directly scavenge and neutralize ROS and free radicals, increase
intracellular GSH, prevent glutamate mediated Ca2+ influx, and modulation of signaling
pathways involved in cellular survival.1,51,52 Oxidative modification irreversibly changes
structure and prevents normal function of macromolecules, however the presence of
flavonoids is able to protect these molecules from MG mediated modification into AGEs
through direct neutralization of ROS and prevents the oxidation of proteins, amino acids,
lipids, metal ions, and other macromolecules.37,51,55 Flavonoid treatments induce
expression of antioxidant proteins and exhibit the ability to influence intracellular GSH
concentrations, increase GSH protein expression, and increase mRNA transcript levels
of both GSH constituent subunits.68-71,114 GSH is a primary constituent of the GP, and
one of the most important endogenous antioxidants for neutralization of dicarbonyl
compounds and maintaining redox balance in cells.52,68,69,71,122 GSH is also an essential
substrate of astrocytic MG detoxification in the brain, and is critical for prevention of
glutamate mediated apoptosis.23-25,68,114 Elevated levels of glutamate are cytotoxic and
deplete intracellular stores of GSH, leading to a decrease in activity of Glo-1 and
induction of apoptosis via influx of Ca2+, however flavonoids reduce intracellular Ca2+
influx in the presence of toxic levels of glutamate.23,114
Flavonoid molecules can regulate cellular, immune, and metabolic processes through
modulation of cell signaling pathways including nuclear factor kappa-light-chainenhancer of activated B cells (NF-kB), mitogen activated protein kinases (MAPK), and
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nuclear factor erythroid 2-related factor 2 (Nrf2).37,123-127 Flavonoids can reduce gene
expression of proapoptotic and proinflammatory products and also inhibit activation of
kinases and phosphatases that contribute to apoptotic cell death.128 ROS are used as
signaling molecules during immune responses, and the presence of antioxidants can
prevent ROS mediated phosphorylation of molecules and pathway targets, preventing
their activation and transcription.2,8,10,15,70 Flavonoids exhibit neuroprotective activity and
can enhance the GP by modulating signaling pathways involved in cellular proliferation
and survival, GSH synthesis, and expression of antioxidant proteins.1,37,51,128
After a flavonoid is oxidized by a free radical, the resulting quinones are involved in
signaling pathways involved in cellular antioxidant and repair activities (FIG 1-3).8,13,15,129
Flavonoids have shown effectiveness in modulation of GP and MG detoxification; our
previous research (Chapter 2) has shown treatment with catechin, morin, and quercetin
was able to attenuate the effects of MG toxicity while retaining cellular function.1,37 The
flavonoids increased Glo-1 activity and GSH concentration, while reducing the
concentration of MG.1,37 While a lack of flavonoids does not cause any disease,
exogenous antioxidants can influence cellular health and offer protection against
inflammatory and degenerative diseases.18,19,75,76,117,130 A correlation exists between
flavonoid consumption and low levels of dementia and neural pathology.19,92,120,131,132
Silymarin and naringin are flavonoids that have shown efficacy in protection against
excitotoxicity in dopaminergic neurons.78,101,102,133 Silymarin protected mice against 1methyl-4-phenylpyridinium (MPP+) induced toxicity by attenuating production of
inflammatory cytokines, and prevented mitochondrial dysfunction.78,101,102,133 Naringin
protected neural cells from toxicity mediated by 6-Hydroxydopamine (6-OHDA),
mediated by an increase in Nrf2 activation.134 Morin has also shown to mitigate the
damage caused by ischemia and stroke by downregulating expression and release of

17
proinflammatory cytokines.135,136 A grape powder extract was shown to reduce anxietylike behavior, depression, and memory impairments caused by elevated OS.63
Dietary habits are an influential factor in developing diseases, including neurological
disorders, diabetes, and cardiovascular disease.75,130 Several longitudinal, cohort studies
determined an inverse relationship between flavonoid intake and all-cause mortality and
cardiovascular disease associated deaths, and also determined that dietary flavonoid
intake positively influenced markers of cardiovascular disease.137 Intake of flavonoids
catechin and quercetin were associated with lower all-cause mortality, and moderate to
high intake of dietary flavonoids in groups with unhealthy lifestyle activities (tobacco use,
alcohol consumption, obesity, and physical inactivity) significantly reduced the all-cause
mortality in research subjects.137
Flavonoid compounds have shown tremendous potential in vitro, and in vivo with animal
models, however their clinical effectiveness in humans has not exhibited the same
successes.131 Animal models utilizing flavonoid compounds as pharmacological agents
are commonly administered through I.P. injection or dietary intake; however, the oral
treatment concentrations are much higher than could be achieved through regular
dietary intake.131 While flavonoids are ubiquitously produced in plants, fruits, vegetables,
nuts and seeds, the relative inefficiency of their breakdown and utilization by the human
body results in circulatory concentrations below the therapeutic dose – no doubt a
contributor to the less-than-stellar clinical results.50,116,131 The bioavailability of flavonoids
and concentrations in blood and tissue are dependent upon absorption, distribution,
metabolism, and excretion, all of which are influenced by the chemical structure of the
flavonoid compounds.138 After ingestion, flavonoids are modified by enzymes in the
digestive tract and liver, which can alter the flavonoids’ biological functions; the
breakdown and metabolism of flavonoids limits the physiological concentrations to levels
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below a therapeutic threshold, preventing their efficient distribution and accumulation
into critical tissues, including the brain.50,138-140 The blood-brain-barrier (BBB) is a
dynamic membrane that limits and prevents molecules in circulatory system from
reaching the brain.141 While flavonoids have lipophilic characteristics, they often exhibit
the inability to permeate the BBB.131,141,142 Extensive digestive and hepatic modifications
- in addition to limited BBB permeability - contribute to the relatively low bioavailability
and activity of dietary flavonoids in humans.50,116,138 Thus, efforts have been made to
improve the bioavailability of flavonoids through modification of chemical structures, and
the use of enhanced drug delivery techniques including nanoparticle encapsulation
(covered in further detail in Chapter 3).50,138
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FIGURE 1-4: NRF2 SIGNALING PATHWAY.
The Nrf2 pathway is activated in response to ROS and oxidative compounds. Nrf2 is
retained in the cytoplasm through interaction with Keap-1 and Cul-3. Under normal
cellular environments, Nrf2 is ubiquitinated and degraded. During states of OS, ROS
disrupt the Nrf2 complex and Nrf2 is translocated to the nucleus for gene transcription.

Nrf2 Activation by Flavonoids
Under states of inflammation and cytotoxicity, cells initiate protective mechanisms
through activation of antioxidant signaling pathways; the Nrf2 pathway is one of the
primary cytoprotective mechanisms utilized to counteract the damaging effects of
OS.56,70,129,143-146 Nrf2 function is dependent upon the cellular environment, making it
highly responsive to changes in oxidative state: normal cellular conditions cause Nrf2 to
be degraded in the cytoplasm, whereas oxidative conditions cause it to translocate to the
nucleus.53,56,70,144,147,148 Nrf2 forms a cytoplasmic complex with Kelch-like ECHassociated protein 1 (Keap1) and E3 ubiquitin ligase Cullin-3 (Cul-3).53, 56, 72 Cul-3
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facilitates ubiquitination and degradation, while Keap1 functions as an adaptor for both
proteins, and a sensor of OS. 53, 56, 72 Under normal physiological conditions,
unstimulated Nrf2 is sequestered in the cytoplasm through interaction with the Keap1Cul3 complex.53, 56, 72 Cul-3 is a protein in the E3 ubiquitin ligase family, and functions to
ubiquitinate Nrf2 and cause it to be degraded in proteasomes.53,56,70,144,147,148 In an
oxidative environment, ROS enter the cell and phosphorylate cysteine residues located
on Keap1, preventing interaction between components of the Nrf2 complex; this
disruption of the Keap1-Cul-3 ubiquitination process prevents the degradation of
Nrf2.53,56,70,144,147,148 Nrf2 is released from the complex, revealing multiple nuclear
localization signals and subsequently translocates to the nucleus.70,129,144 Nrf2
heterodimerizes with transcription factor Maf, and binds to the antioxidant response
element (ARE) in promoter regions of gene targets, initiating transcription of antioxidant
proteins, including Glo-1, heme oxygenase-1 (HO-1), catalase (CAT), superoxide
dismutase (SOD), NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione peroxidase
(GPx) and enzymes involved in GSH function and synthesis, glutathione-S-transferase
(GST), l-glutamylcysteine ligase (GCL) (FIG 1-4).58,132,144-147
The Nrf2 pathway is highly responsive to changes in the redox state of cells, and is
critical for mediating expression of cytoprotective proteins during states of
OS.58,129,144,145,147 Activation of Nrf2 in response to elevated MG concentrations can
prevent cellular damage and cytotoxicity, and Nrf2-ARE interaction increased Glo-1
mRNA transcription, protein expression, and activity, resulting in decreases of both MG
and AGEs.70,129,143,144,147,148 Treatment with Nrf2 activators prevented apoptosis, and
reduced the accumulation of levels MG-mediated protein carbonylation, while
significantly elevating mRNA expression of GCL, an enzyme involved in GSH
synthesis.58,70,144,145 The observed cytoprotection against MG was a result of GSH
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expression - in a GP dependent mechanism - as evidenced by the increase in D-lactate
after Nrf2 activation.1,37 Cells treated with Nrf2 inhibitor buthionine sulfoximine did not
exhibit a protective effect.1,37 Flavonoid curcumin demonstrated the ability to induce Nrf2
activation by inhibiting ubiquitination, through direct interaction with Keap1 and
subsequent disruption of complex proteins.149
Flavonoids are able to indirectly induce Nrf2 expression by activation of kinase pathways
resulting in phosphorylation of Nrf2 and induction of dependent genes.37,135,147,150-152
Flavonoid mangiferrin upregulated Glo-1 via activating Nrf2/ARE signaling
pathway.67,123,152 Flavonoids are able to prevent ROS production and apoptosis through
interaction with signaling pathways.1-3,10,53,60,133,135 Flavonoids modulate proinflammatory
signaling pathways, and can inhibit expression of TNF-α by modulating NF-κB, and
reduce activation of the JNK/AP-1 pathway, inducing expression of antioxidant
molecules like mitochondrial PNO2, which exerts its neuroprotection primarily through
protecting against mitochondrial-mediated OS.129,132,144,146,151 Flavonoids were found to
reduce MG, and also inhibit AGE formation by preventing formation/presence of
dicarbonyl compounds, and enhance GP activity.37,51,55,147 The GP is an integral part of
the body's antioxidant system, and dysfunction can have deleterious and catastrophic
events, resulting in elevated production of ROS which can further and exacerbate
neurodegenerative disease.5,45,46,48,49,69,86,97 This pathway found in all cells of our body
can be responsible for production and formation of toxic intermediaries that alter a cell's
normal function and contribute to the severity of aging and neurodegenerative
diseases.1,3,20,21,37,40,48,102,153 The GP is a promising drug target for inflammatory diseases,
making it an attractive target for neurodegenerative disease.
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CHAPTER 2: FLAVONOIDS ENHANCE NEURAL
GLYOXALASE PATHWAY IN A METHYLGLYOXAL
MODEL OF AGING AND ALZHEIMER’S DISEASE
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INTRODUCTION
The GP involves sequential reactions – utilizing GSH, Glo-1 and Glo-2 - to prevent the
buildup of MG and other carbonyl molecules, reducing the driving factors of ROSmediated inflammation (FIG 1-1).1,20-22,34,37,38 The resulting inflammation is fed by a
perpetual cycle of elevated ROS production, inflammatory cytokine and chemokine
signaling, and chronic immune activation.2,8,10,13,15 Accumulation of MG results in
disequilibrium of the body’s redox environment, resulting in an inflammatory state of OS,
known to drive the progression of neurodegenerative diseases and accelerate the aging
process.7,13,19 The GP antioxidant system is crucial in neural defense against OS and
inflammation mediated by MG and other reactive dicarbonyl compounds.
Pharmacological modulation of antioxidant pathways can bolster their effectiveness and
prevent the accumulation and production of ROS and other inflammatory
compounds.19,75,76,117,129 Flavonoids are a class of polyphenol molecules with antiinflammatory activity, and have emerged as viable candidates for enhancement of
endogenous antioxidant systems.1,37,51,55,122,130 This family of naturally-produced,
secondary plant metabolites consists of over 4000 identified compounds, and possess a
wide range of biological activity.51,55,116 Their effects are contingent upon cell and tissue
type, the surrounding microenvironment, and the composition and configuration of
chemical structure.37,51,55,116,130 For example, flavonoid treatment can increase the
viability of normal cells, while also acting as inhibitors in some cancer cell lines.55,67,123,126
Quercetin (3,3’,4’,5,7-pentahydroxy flavone) and morin (2’,3,4’,5,7-pentahydroxy flavone
(FIG 2-1) treatments were found to be cytoprotective in primary cerebellar neurons, but
promoted apoptosis in glioblastoma cells and colon cancer cells, respectively.37,123,126
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The polyvalent, versatile activity of

A

flavonoids and their ubiquitous
production in nature has
increasingly made these
compounds the focus of drug
related research. 28,54,61,62,147,155 The
anti-inflammatory activity of some

B

flavonoids, relatively efficient
bioavailability, and ability to cross
the BBB has resulted in their
therapeutic use for
neurodegenerative
diseases.1,9,116,154 Flavonoids’
antioxidant activity allows them to

C

directly bind and neutralize ROS,
reactive nitrogen species (RNS),
and metal ions, and are incredibly
efficient at promoting cell viability in
the presence of highly oxidizing
agents, like H2O2 and
MG.28,54,61,62,147,155 While flavonoids
can directly reduce ROS and free

FIGURE 2-1: FLAVONOID STRUCTURES.
The chemical structures of flavanol catechin (A),
and flavonols morin (B), and quercetin (C).

radicals, the mechanism of their
protective function is mediated
through modulation of antioxidant and apoptotic signaling pathways, chiefly Nrf2 and NFkB.58,62,123,127,143,144,146,147,152,156-161 MG plays a role in the progression of AD, and
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negatively contributes to disease pathological hallmarks Ab, NFTs, and loss of neuronal
viability.26,32,33,35,87,97,162
Quercetin is a widely distributed and common polyphenol flavonoid (found in high
concentrations in capers, sorrel, radishes, red onions, and kale), with a wide range of
bioactivity, and exhibits anti-inflammatory, anti-viral, anti-cancer activity, and has found
to be cytoprotective in cells of the liver, kidneys, heart, and brain.28,163,164 Its
neuroprotective effects have been documented in a variety of disorders, including HD,
MS, diabetes, PD, and AD, and has been shown to protect against cognitive
deficits.9,164,165 Quercetin was shown to be neuroprotective – through a GP-mediated
mechanism - in a rat model of streptozotocin-induced diabetic cognitive decline.57
Quercetin treatment reduced levels of blood glucose, and inflammatory signaling
molecules COX-2, IL-1b, and TNF-a, while elevating antioxidant activity of superoxide
dismutase (SOD).57 Quercetin was found to directly modulate the GP by increasing Glo1 activity and GSH levels, decreasing AGEs, and reducing expression of RAGE.57
Quercetin has shown potent neuroprotective activity in AD.9,53,124,166 Mouse hippocampal
neurons insulted with Ab and H2O2 showed markedly reduced neurotoxicity and ROS
production when treated with quercetin.167 It also prevented metabolic dysfunction by
protecting mitochondrial membrane integrity and morphology.167 Transgenic AD mice
treated with quercetin exhibited attenuated disease pathology and neurobiological
deficits.166 Histological analysis of brain tissue from triple-transgenic AD mice (3xTg-AD)
revealed a retention of cell morphology and cell density.166 Quercetin treatment was
remarkably efficacious against pathological hallmarks of AD, reducing levels of both Ab
and NFTs in the cerebellum and hippocampus of 3xTg-AD mice.166 The neuroprotective
effect of quercetin was evident through a reduction in activated astrocytes and microglia,
mediators of neuroinflammation in neurodegenerative diseases.166 The functional results
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of these reduced pathologies were improvements in spatial learning, memory, and
anxiety-like behavior.166 Quercetin protected mouse hippocampal neuron morphology
and viability in an okadaic acid-mediated OS model of AD.124 The anti-inflammatory
effects of quercetin were evidenced by an elevation in GSH and SOD, reductions of
malondialdehyde (a marker of glycation) and ROS, retention of mitochondrial membrane
permeability, and reduced caspase-mediated apoptosis.124 Hyperphosphorylation of tau
– the initiating factor in NFT formation – was significantly suppressed in neurons treated
with quercetin.124 Apoptotic signaling pathways commonly associated with AD – Akt,
GSK-3b, and MAPK – were inhibited by quercetin treatment.124 Hypoxia-induced
mitochondrial dysfunction in rats was prevented by quercetin supplementation, with
quercetin treated animals exhibiting drastically reduced memory impairments compared
to the control cohorts.159 Acrylamide is known neurotoxin and induces OS through the
same mechanism as MG, the generation of reactive carbonyls through the Maillard
reaction.168 Quercetin treatment in rats insulted with acrylamide exhibited normalized
expression of neurotransmitters serotonin and dopamine, and reduced concentrations 8hydroxy-2-deoxyguanosine (8-OHdG), a marker of OS-mediated DNA damage.168
We hypothesize that treatment of neurons with exogenous antioxidant compounds
reduces the oxidative burden of MG by enhancing the GP. To test this hypothesis, we
utilized three well-known flavonoid compounds – flavanol catechin and flavonols morin
and quercetin – and investigated their effects on GP function in mouse primary
cerebellar neurons induced to a state of OS with MG. The purpose of this study is to
provide evidence of flavonoids’ ability to enhance the GP and elucidate the functional
mechanisms. Through evaluation of GP substituents, signaling pathway activation,
apoptosis, and neurotransmitter function, we determined all three flavonoids to be
neuroprotective in an MG-mediated OS model of AD.37 The specific mechanisms of
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protection involved: Nrf2-mediated upregulation of Glo-1, Glo-2, GSH, and MG
detoxification, retention of excitatory and inhibitory neurotransmission, reduction of
caspase-mediated apoptosis, and inhibition of NF-κB signaling.37
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MATERIALS AND METHODS
Care and use of animals
Animal studies were approved and performed in accordance with the UNMC Institutional
Review Board (IRB) and Institutional Animal Care and Utilization Committee (IACUC).
C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME).
Chemicals and compounds
Morin was purchased from MP Biomedicals (Solon, OH). Quercetin dehydrate was
purchased from Pfaltz & Bauer, (Waterbury, CT). Sodium D-lactate was purchased from
Santa Cruz Biotechnology (Dallas, TX). Lactate dehydrogenase was purchased from US
Biological (Salem, MA). Catechin Hydrate, Poly-D-lysine hydrobromide, β-nicotinamide
adenine dinucleotide hydrate, methylglyoxal, and 2,4-Dinitrophenylhydrazine were
purchased from Sigma Aldrich (St. Louis, MO). Unless otherwise noted, chemicals for
this study were purchased from Thermo Fisher Scientific (Fair Lawn, NJ).
Cerebellar neuron culture
Primary cultures of cerebellar neurons were prepared from P3-5 C57/BL6 mice. Six well
culture plates (Falcon, Indianapolis, IN) were coated with poly-D-lysine and seeded with
cerebellar neurons at a density of 1.5 × 106 cells/well, and maintained with DMEM media
supplemented with L-glutamine, pen-strep, 30% sucrose, B-27, and N-2. Ara-C was
added 24 hours after seeding to produce a homogenous neuronal culture. Cells were
grown to confluence for 6 days, with half media changes every 48 hours. The negative
control received no treatment, the vehicle was treated with 500 μM MG. Antioxidant
treatment groups were treated for 24 hours by adding 500 μM MG first and followed by
10 μM flavonoid.37
Western Blot Analysis.
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Cerebellar neuron cultures were washed with ice cold PBS three times and lysed using
RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X100, 1% Na deoxycholate
0.1% SDS, 1 mM EDTA) and a protease inhibitor cocktail (Thermo-Fisher). A BCA assay
(Pierce) was used to ensure equal protein loading content. Samples were added to a
loading buffer (LDS sample buffer 4X, b-mercaptoethanol, PBS) and denatured at 90 °C
for 5 minutes. Proteins were resolved on a 4–20% tris-glycine gel (Bio-Rad) using SDSPAGE, and transferred to a PVDF membrane (Immobilon). Membranes were blocked for
1 h in TBST and 5% fat free milk (BioRad), washed in TBST, and incubated overnight at
4 °C with antibodies directed against Glo-1 (Rabbit polyclonal, Santa Cruz), Glo-2 (Goat
polyclonal, Santa Cruz), and p-Akt (Rabbit polyclonal, Cell signaling). Blots were washed
and incubated with the appropriate HRP-conjugated secondary antibody (Santa Cruz).
β-actin expression (Rabbit monoclonal, Cell Signaling) was assessed to ensure equal
protein content.37
Determination of D-lactate concentration
Media samples from cerebellar cultures were collected prior to lysing the cells. D-Lactate
released into the extracellular space following treatment with MG and antioxidant was
measured spectrophotometrically. Culture media samples of 70 µL were loaded on a 96well plate with 180 µL of glycine buffer (0.2 M glycine, 0.2 M semicarbazide, pH 10),
containing 2 mg/mL NAD and 5 U/mL D-lactate dehydrogenase. Samples were
incubated at room temperature for 2 hours. A spectrophotometer (340 nm excitation, 450
nm emission) was used to measure conversion of NAD to NADH. Absolute values were
determined from a standard curve of D-Lactate concentrations.34
Determination of MG concentration
A 10 mM stock solution of 2,4-DNPH (Sigma-Aldrich, St. Louis, MO, USA) in 100%
ethanol was used to create a working solution of 0.2 mM 2,4-DNPH with 12 mL HCl
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(36%) per 100 mL ethanol. A working solution of 1 mM MG (Sigma) was prepared from a
stock solution. The reaction consisted of 950 µL 0.2 mM 2,4-DNPH with different
volumes of 1 mM MG, filled to 1 mL with media for the blank, or 50 mL of media from
cerebellar neuron culture. The samples and blanks were heated in an Eppendorf
Thermomixer at 42 °C for 45 mins and 600 rpm, and were incubated at room
temperature for 5 minutes. Spectrophotometer measurements were performed at 432
nm, according to absorbance of MG-bis- 2,4-DNPH-hydrazone for calculating
concentration of MG.169
Glo-1 activity
Neurons were plated in 12 well plates at 5 × 105, and grown to maturity at 6 days. Cells
were treated with 500 μM MG and 10 μM antioxidant for 24 hours. Media was removed,
and cells were rinsed with ice cold PBS. Cells were lysed with buffer containing: 10 mM
HEPES (pH 7.0), 0.02% Triton X-100, and 100 μg/ mL BSA. Samples were briefly
sonicated and centrifuged at 16,000 g for 30 minutes at 4 °C. Cellular lysates were
added to a 96 well plate at 50 µL per well. Reaction mix consisted of 60 mM sodium
phosphate pH 6.6 containing 4 mM GSH and 4 mM MG. Two hundred µL reaction mix
was added to the 96 well plate and incubated for 10 minutes at 37 °C, and 50 µL of
sample lysate was added to the plate. S-lactoylglutathione synthesis was determined by
measuring absorbance at 240 nm every 15 seconds for 5 minutes. Protein concentration
was determined using a BCA protein assay reagent kit (Thermo Scientific).37
Determination of GSH concentration
Total intracellular glutathione levels were determined spectrophotometrically. Levels of
total glutathione and oxidized glutathione (GSSG) were determined and used to
calculate levels of GSH. Values were calculated from a standard curve of GSSG.37
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Immunocytochemistry
Primary cerebellar neurons were harvested from P5 C57/BL6 mice. Neurons were plated
in 8 well imaging plates at 300,000 cells/well. After growing for 6 days, cells were treated
with 500 μM MG and 10 μM flavonoids for 24 hours. Media was removed and cells were
fixed with 4% PFA/30% sucrose solution in PBS for 10 mins. Wells were washed with
PBS (0.1% Triton 100-X) in PBS for 10 mins. Wells were again washed with PBS, and
blocked with 5% BSA in PBS at room temperature for 1 hour. Primary antibodies for
NeuN (mouse monoclonal) and cleaved caspase-3 (mouse monoclonal), and VGLUT1
(guinea pig polyclonal) and GAD65 (rabbit monoclonal) were added in 1% BSA in PBS
overnight. Wells were washed with PBS, and incubated with the appropriate IgG (H + L)
conjugated secondary antibodies at room temperature for 1 hour. Wells were washed,
and covered with DAPI stain for 30 seconds. DAPI stained cells were washed and
aspirated, and Prolong Gold Antifade (Thermo Fisher Scientific, MO) was added directly
to each well. Plates were imaged on a confocal microscope (LSM 710 Zeiss Confocal
Microscope) at 20-40x.37
Statistics
Statistics were performed using Excel (Microsoft) and SPSS (IBM Corporation). Data
were expressed as the mean +/− SEM of multiple experiments performed in triplicate.
Statistical differences between means were analyzed using a student’s t-test or one-way
analysis of variance (ANOVA). Data with at least p<0.05 was considered statistically
significant.37
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RESULTS
MG and Flavonoid Cytotoxicity
Accumulation of MG is commonly
present during aging and in
neurodegenerative disorders, and
mediates an inflammatory cellular
environment.24,25,64 In this study, we
utilized MG as a means to induce the
OS that contributes to the
pathogenesis of AD. To determine the
appropriate concentration of MG for
induction of OS, we treated cerebellar
neuron cultures with a range of MG
concentrations to determine the most
appropriate concentration for induction

FIGURE 2-2: CYTOTOXICITY OF MG AND FLAVONOIDS.
Determination of treatment dosage level for cerebellar
neurons was determined through an MTT assay using
various concentrations of MG (A) and flavonoids (B).

of OS. Through an MTT assay, we
determined 500 µM was the optimal concentration to induce OS without excessive
cytotoxicity.37
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FIGURE 2-3: ANALYSIS OF GP FUNCTION.
Cultured cerebellar neurons were induced to a state of OS with MG [500 µM], treated with
flavonoids [10 µM] (Control = no MG, Vehicle = only MG) and markers of GP function were
measured. (A) D-lactate release into extracellular space #P < 0.05 (vs Control), *P < 0.05 (vs
Vehicle). (B) Concentration of MG [μM/mL] #P < 0.05 (vs Control), *P < 0.05 (vs Vehicle). (C)
Concentration of GSH ##P < 0.01 (vs Control), *P < 0.05 (vs Vehicle), **P < 0.01 (vs
Vehicle). (D) Glo-1 activity #P < 0.05 (vs Control), *P < 0.05 (vs Vehicle). Values are means
+/− standard error of samples performed in triplicate from several independent experiments.

Flavonoids Increase MG Detoxification
GP function can be assessed by measuring the concentration and activity of substituent
proteins. The concentration of D-lactate in the extracellular space provides a means to
measure the detoxification of MG by the GP. D-lactate concentration was determined by
spectrophotometrically measuring the conversion of NAD to NADH. To induce a state of
OS, cerebellar neuron cultures were insulted with MG [500 µM] for 24 hours, and treated
with flavonoids [10 µM] to determine its effect on GP function. Catechin, morin, and
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quercetin treated cerebellar neurons had a significantly higher concentration of D-lactate
than the MG treated control (FIG 2-3A). The media from MG treated cells contained 0.7
mM of D-lactate, while the flavonoid treated groups had D-lactate concentrations in
excess of 1 mM. The increase in D-lactate concentration in the presence of flavonoids
indicates that the GP is enhanced and MG has been detoxified in high amount. The
reaction of MG with 2,4-DNPH produces dinitrophenylhydrazone, which was measured
spectrophotometrically to determine the MG content. Catechin, morin, and quercetin
were able to significantly decrease the concentration of MG compared to the MG-treated
control (FIG 2-3B). Flavonoid treatment attenuated MG accumulation, with MG
concentration in flavonoid treated cells similar to levels of the non-treated control. This
result matches when correlated with increase in lactate concentration.
Flavonoids Increase GSH Concentration and Glo-1 Activity
GSH is a protein utilized for antioxidant defense. In the GP, it catalyzes the first step in
the conversion of MG to D-lactate. High concentrations of MG deplete the intracellular
concentration of GSH, preventing efficient functioning of the GP. MG treatment
drastically decreased the concentration of GSH in neural cell cultures, however this
effect was prevented significantly by flavonoid treatments (FIG 2-3C). Catechin resulted
in a significant increase in GSH, and morin and quercetin were able to increase GSH
levels to that of the untreated control. The glyoxalase activity assay evaluated the
capacity of the cerebellar neurons to detoxify MG. Glyoxalase activity measures the
mU/mg protein of Glo-1 needed to catalyze the conversion of the GSH-MG
hemithioacetal into S-D-lactoylglutathione. MG treatment of 500 μM significantly reduced
the activity of Glo-1 in cerebellar neurons, while flavonoid treatment decreased the Glo-1
activity inhibition caused by MG (FIG 2-3D). Catechin, morin, and quercetin were found
to significantly increase Glo-1 activity compared to the MG treated control.
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Flavonoids Prevent Cleaved Caspase-Mediated Apoptosis

FIGURE 2-4: EFFECTS OF FLAVONOID TREATMENT ON CELL VIABILITY AND APOPTOSIS.
Cerebellar neurons were treated with flavonoids [10 μM] and MG [500 μM]. Data was determined via
immunocytochemistry (A). Viability was assessed through detection of cleaved caspase-3 (C-Cas-3)
(B) and neuronal specific nuclear protein (NeuN) (C). Control = no MG, Vehicle = only MG. Values
are means +/− SEM of samples performed in triplicate from several independent experiments, n = 3–
4. #P < 0.05 (vs Control), *P < 0.05 (vs Vehicle). Images were quantified with ImageJ, and resulting
data were analyzed using an ANOVA. Morin treatment significantly decreased the presence of
apoptosis, and catechin and morin significantly increased cell viability.
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MG promotes the activation and subsequent cleavage of caspase-3 (Cas-3), which is a
regulator of apoptosis and triggers cell death through a mitochondrial-mediated
pathway.34,46 Cerebellar neuron cultures underwent a 24 hour treatment with MG and
flavonoids, and were fixed for immunocytochemistry. Cells were conjugated with
antibodies directed towards cleaved caspase-3 (C-Cas-3) and neuronal specific nuclear
protein (NeuN) to determine apoptosis and survival, respectively. Relative fluorescence
was determined through confocal microscopy imaging. MG treatment significantly
increased the amount of Cas-3 positive cells, and decreased the amount of NeuN
positive cells compared to the non-treated control. This increase in apoptotic cells was
prevented by flavonoid treatment. A significant decrease in the amount of Cas-3 positive
cells was found in the catechin, morin, and quercetin treated conditions (FIG 2-4B). A
significant increase in the amount of NeuN positive cells compared to the MG-treated
control was found in the catechin and morin treated conditions (FIG 2-4C). These results
suggest flavonoid treatments increase survivability of cerebellar neurons in the presence
of cytotoxic MG.
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Flavonoids Protect Excitatory and Inhibitory Neurotransmission

FIGURE 2-5: FLAVONOID TREATMENT ON EXCITATORY AND INHIBITORY SYNAPTIC FUNCTIONS.
Functions were assessed through immunocytochemistry. Representative images
showing DAPI, VGLUT1, and GAD65 in flavonoid (10 μM) and MG (500 μM) treated
cerebellar neurons (A). Excitatory and inhibitory synapse function was assessed
through detection of VGLUT1 (B) and GAD65 (C). Control = no MG, Vehicle = only
MG. Values are means +/− SEM of samples performed in triplicate from several
independent experiments, n = 3–4. #P < 0.05 (vs Control), *P < 0.05 (vs Vehicle).

Glutamate and g-amino butyric acid (GABA) are the principal excitatory and inhibitory
neurotransmitters (respectively) utilized by neurons for cell-to-cell communication and
signal propagation; the balance of both excitatory and inhibitory neurotransmission is
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critical for neurological function and environmental homeostasis.170 Excitatory
neurotransmission was determined through evaluation of vesicular glutamate
transporter-1 (VGLUT), involved in transport of glutamate into the synaptic cleft;
inhibitory neurotransmission was determined through evaluation of glutamic acid
decarboxylase-65 (GAD65), involved in conversion of glutamate to GABA.170 The
expression of both GAD65 (FIG 2-5B) and VGLUT1 (FIG 2-5C) in DAPI-positive cells
were significantly reduced with the addition of MG compared to the control, indicative of
drastic deficits in neurotransmission. However, MG insulted cells treated with catechin,
morin, or quercetin exhibited significantly higher expression of GAD65 and VGLUT1 in
DAPI-positive cells compared to the MG treated cells alone. Flavonoids prevented MGmediated decreases in neurotransmission, and neurons retained both excitatory and
inhibitory neurotransmitter function. While all tested flavonoids significantly elevated
neurotransmitter function in the presence of MG, morin treatment resulted in expression
levels similar to the control group.
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Flavonoids Increase Glo-1 and Glo-2 Expression and Prevent Akt Phosphorylation

FIGURE 2-6: FLAVONOID TREATMENT ON GLYOXALASE PROTEIN EXPRESSION.
Proteins Glo-1 (B), Glo-2 (C), and P-Akt (D). Representative Western Blot images (A). Values are
means +/− SEM of samples performed in triplicate from several independent experiments, n = 3–
4. *P < 0.05 (vs Control). Expression of P-Akt in cerebellar neurons was assessed via Western
Blotting. Cerebellar neurons were treated with MG (500 μM) and flavonoids (10 μM). Blots were
conjugated with β-actin to ensure equal protein loading. Control = only MG. Values were
determined using ImageJ. Resulting data were analyzed using an ANOVA. A significant decrease
(*p < 0.05) in P-Akt was found in the catechin and quercetin treated groups (10 μM) compared to
the MG treated control.

The efficiency of the GP to detoxify MG is predicated upon the presence and activity of
Glo-1 and Glo-2 proteins, with positive correlations between protein expression and MG
detoxification.1,20-22,86 Protein expression of Glo-1, Glo-2, and P-Akt in cerebellar neurons
was determined through western blotting (FIG 2-6D). Flavonoid treatment in MG-insulted
cells significantly increased the expression of both Glo-1 (FIG 2-6A) and Glo-2 (FIG 26B) compared to cells treated only with MG.
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The PI3K-Akt pathway influences NF-κB signaling, with activation of Akt (protein kinase
B) causing phosphorylation of IKKa, degradation of IκB, and subsequent NF-κB nuclear
translocation.124,126 MG treatment resulted in elevated expression of P-Akt, which was
abolished in neurons also treated with flavonoids treatment in MG-insulted cells reduced
P-Akt (FIG 2-6C). Catechin and quercetin treatments in MG-insulted neurons
significantly reduced phosphorylation of Akt compared to the MG treated cells alone.
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DISCUSSION
This study investigated the effects of flavonoids on GP function. Here we provide
evidence that catechin, morin, and quercetin can enhance the GP and attenuate MGmediated toxicity in neurons.1,37 Our in vitro experiments utilized primary cerebellar
neurons insulted with MG to recreate the cellular environment commonly found in
pathological aging, AD, and neurodegenerative diseases.13,33,35,60,77,92,171 MG
accumulation and GP dysfunction are implicated in accelerated aging of neural cells and
progression of AD pathology, and attenuating the driving factors of ROS-mediated
inflammation can reduce disease severity.26,33-35,64,87,97,162 At relatively low
concentrations, flavonoid treatments had robust influences on GP function, nearly every
aspect of the GP was improved with flavonoid treatments: elevated expression of Glo-1
and Glo-2 proteins, increased concentrations of GSH, elevated Glo-1 activity, and
increased detoxification of MG to D-lactate.37 Even under conditions of extreme
cytotoxicity, flavonoids exhibited the ability to attenuate MG-mediated cellular damages.
Cerebellar neurons increased the rate of their endogenous antioxidant system through
flavonoid supplementation. In accordance with this, we observed a decreased
concentration of MG in the media. Reducing the concentration of MG will reduce the
production of ROS, proinflammatory cytokines, AGEs, and oxidized molecules, which
provoke a chronic immune response and directly lead to conditions of OS.21,31-35
Reducing the oxidative burden on the GP allows its antioxidant functions to be more
efficient and prevent the exponential rise of toxic molecules in the cellular milieu.
Reduced expression of the constituent pathway proteins has been linked to premature
aging, and increased severity of neurodegenerative disease.3,20,21,64,86,87 Increased
expression of glyoxalase proteins has been shown to lower formation of ROS and free
radicals, and elevated levels corresponded to a decrease in concentration of a-
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oxoaldehydes.38,39,57,58,172 MG detoxification requires the presence of both Glo-1 and Glo2, and a decrease in either pathway protein would prevent efficient pathway function and
have a dramatic negative impact on neuronal viability.3,20,21,38,48,58 MG-induced toxicity
can alter synaptic morphology through disruption of uptake and release of
neurotransmitters, negatively impacting the neural communication and signaling.10,170
Flavonoid treated cerebellar neurons were able to effectively retain the structure and
function of both excitatory and inhibitory synapses.37 Accumulation of glutamate in the
synapses is a trigger for a cellular influx of Ca+2, which initiates an apoptotic signaling
cascade.11,55,116,136 We found flavonoid treatment positively increased markers of
glutamate and GABA receptor function in the presence of MG.37 These neurons were
able to more efficiently convert glutamate to GABA, and clear glutamate from the
synaptic cleft. Flavonoids also had a significant impact on cell viability by decreasing the
activated form of caspase-3. Cleavage of this protein initiates mitochondrial mediated
apoptosis, releasing other pro-apoptotic proteins and resulting in destruction of the
mitochondria and death of the cell.11,17,135,173 NF-κB signaling is initiated in response to
cellular damage, inflammation, and cytokine release, which can be directly and indirectly
influenced by MG concentrations.123,152,161 The NF-κB heterodimer has two subunits
(p65, p50) and is sequestered in the cytoplasm when bound to its inhibitory subunit,
IκBα.123,129,152,174 Phosphorylation degrades the inhibitory subunit - IKKβ - and NF-κB is
translocated to the nucleus for rapid initiation of apoptotic gene transcription. 123,129,152,174
MG and ROS mediate inhibitory subunit phosphorylation, thus regulating the
transcription of pro-apoptotic protein products. 123,129,152,174 Decreasing MG and ROS in
the cell directly reduces the amounts of molecules able to modulate and activate this
signaling pathway.123,174,175 Flavonoids were found to modulate NF-κB signaling through
a reduction in phosphorylation of Akt.51,123,152,161 Reduced P-Akt prevents the activation
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and nuclear translocation of NF-κB, causing it to undergo cytoplasmic degradation.
51,123,152,161

We observed that flavonoids offered protection against MG-mediated OS in cerebellar
neurons, preventing progression of neurodegenerative disorders. These compounds
offer an attractive solution against ROS mediated damage to cells, as they have very low
cytotoxicity, and function to increase the efficiency of the GP. Proper function of the GP
decreases the amounts of ROS, free radicals, and damaging reactive compounds, and
allows for retention of neuronal function. Based on the results of this study, flavonoids
compounds may prove to be an effective treatment for GP-mediated prevention of aging
and neurodegenerative disease.
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CHAPTER 3: EFFECT OF MORIN DERIVATIVES ON
NEURAL GLYOXALASE PATHWAY
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INTRODUCTION
The brain’s high metabolic requirements combined with limited antioxidant capacity
render the organ highly vulnerable to ROS-mediated by damage. 3,6,12,13,19 Ubiquitously
produced MG is highly reactive and alters the structure and function of proteins, lipids,
and nucleic acids through formation of AGEs. 5-17 The GP performs indispensable
functions in the brain by neutralizing and preventing accumulation of MG and producing
an alternate energy source for neurons.22,34,64 Increasing the activity of the GP can
prevent elevated levels of MG in neural cells.1,37,57,58 Thus, the GP is a valid target for
pharmacological intervention in AD and other neurodegenerative disorders, and plantproduced compounds have been widely investigated and utilized for their biological
activity.19,116 Morin is a flavonoid present in a variety of fruits, vegetables, and nuts, with
high concentrations found in plants in the moraceae family (e.g. mulberry and fig).
123,127,133,147,152,161

Morin exhibits antioxidant, anti-inflammatory, and anti-cancer activity,

mediated through modulation of cellular signaling pathways .7,20,24,26 Morin has previously
been characterized as cytoprotective in liver, pancreas, lung, cardiac, and neural cells.2024

Evidence shows morin possesses protective effects in neurodegenerative conditions

including ischemia, MS, PD, and AD. 1,37,55,123,133,135,136,151,152,158,161,173,176 Morin exerted its
control over the NF-κB signaling pathway by attenuating TNF-a induced activation by
inhibiting degradation of IκBα, and was also able to inhibit TNF-a mediated p65 nuclear
translocation.123,127,152,161,177 Morin was shown to decrease survival of cancer cells, while
increasing viability of normal endothelial cells, for example morin inhibited
phosphorylation of Akt in a breast cancer cell line, preventing metastases and tumor
proliferation.174,177
While flavonoid treatments have shown efficacy against AD in vitro and animal models in
vivo, no substantial benefit has been exhibited in clinical trials in AD patients.9,116,131 The
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ineffective results stem from flavonoids not reaching critical areas of brain tissue, which
could be due to premature metabolic degradation, and poor permeability through the
blood brain barrier (BBB).131 Plant compounds are commonly utilized in drug design, as
modification of chemical structural can influence and improve chemical activity.178
Halogens are versatile atoms with a wide variety of chemical functions and commonly
utilized in drug discovery.179 Also, the addition of halogens to compounds is frequently
used in drug design to increase the compound’s lipophilicity, membrane permeability,
oral absorption, and resistance to metabolic degradation, while generally not increasing
toxicity.179
We have previously demonstrated the ability of flavonoids catechin, morin, and quercetin
to enhance the GP to prevent MG mediated OS in neural cells.1,37 As an extension to
this, our current research is focused on creating novel morin structural variations to
improve its inherent antioxidant ability. We synthesized a morin analogue with the
addition of two bromine molecules – Di-bromomorin (DBM) - and a morin encapsulated
nanoparticle (MNP). We hypothesize structural modifications to morin will increase its
ability to enhance the GP in a MG-mediated model of AD. Cultured mouse cerebellar
neurons and strains of C. elegans were induced to a state of OS with MG, and treated
with morin and its derivatives to evaluate the effect on GP function. Through evaluation
of constituent pathway proteins, MG, D-lactate, and imaging of neural structures, we
provide evidence of the GP efficiency increase by structurally modified compounds. Our
research shows the modified morin compounds – DBM and MNP – were more effective
in GP enhancement than the unmodified flavonoid itself.
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MATERIALS AND METHODS
Care and Use of Animals
Animal studies were approved and performed in accordance with the UNMC Institutional
Animal Care and Utilization Committee (IACUC). C57BL/6 mice breeding pairs were
obtained from The Jackson Laboratory (Bar Harbor, ME). C. elegans strains N2 (Bristol),
VC343 (glod-4(gk189)), and CL2006 (dvls2), and Escherichia coli OP50 were purchased
from the Caenorhabditis Genetics Center (CGC) at the University of Minnesota (MN,
USA).
Chemicals and Compounds
Morin was purchased from MP Biomedicals (Solon, OH). Sodium D-lactate was
purchased from Santa Cruz Biotechnology (Dallas, TX). Lactate dehydrogenase was
purchased from US Biological (Salem, MA). Poly-D-lysine hydrobromide, β-nicotinamide
adenine dinucleotide hydrate, methylglyoxal, 5-fluorodeoxyuridine, and 2,4Dinitrophenylhydrazine were purchased from Sigma Aldrich (St. Louis, MO). Antibodies
used were B-Actin (sc-47778), MAP-2 (sc-32791), caspase-3 p17 (sc-373730), HO-1
(sc-390991), GAD-65 (sc-377145), Nrf2 (sc-81342), Glyoxalase I (sc-133214),
Glyoxalase II (sc-166781), m-IgGk BP-HRP (sc-516102), m-IgGk BP-CFL 488 (sc516176), m-IgGk BP-CFL 555 (sc-516177) from Santa Cruz Biotechnology (Dallas, TX);
DJ-1 (5933), P-Akt (4060), IKKa (11930S), IkBa (4812S), P- IKKa (2697S) from Cell
Signaling Technology (Danvers, MA); VGLUT1 (AB5905), NeuN (MAB377) EMD
Millipore (Temecula, CA). Unless otherwise noted, chemicals for this study were
purchased from Thermo Fisher Scientific (Fair Lawn, NJ).
Primary Cell Culture
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Cerebellar neurons were harvested from P3 C57/BL6 (Jackson Labs) as previously
described.34,37 Corning plates were left under UV light for 30 mins, and poly-D-lysine HBr
(MP Biomedicals) was added to wells (150 µg/mL) for 3 hours. Wells were washed three
times with endonuclease-free water. The brains were removed via cervical dissection.
The cerebellum was isolated, and the veins and meninges were removed. The tissue
was treated with 2.5% trypsin for 15 minutes. The trypsin was removed, and 1%
deoxyribonuclease was added and tissue was pipetted gently to form a homogenous
mixture. Cells were centrifuged at 700 x g for 5 minutes. The supernatant was removed,
and 1% DNase was added and resuspended. The solution was then filtered through a
40 µm nylon screen and centrifuged at 700 x g for 5 minutes. The supernatant was
removed, and the pellet resuspended in BME serum media (Fetal Bovine serum, horse
serum, glucose, glutamine). Cells were counted using a hemocytometer and seeded
onto 6-well plates (1.5x106 cells/well), 12-well plates (5×105 cells/well), or 96-well plates
(5x104 cells/well). Media were changed into serum-free DMEM (B27, N2, sucrose,
glutamine, PS) after 4 hours. AraC was added (5 µM) after 24 hours to ensure a
homogenous neural culture. Cells were incubated at 37˚C (5% CO2) with half media
changes every 2 days. Confluent cultures on day 5 were treated with MG (500 µM) and
flavonoid (10 µM), or vehicle (0.1% DMSO) for 24 hours. Media and lysates were
collected and stored at -80˚C.128
Synthesis of Di-bromomorin
2-(2,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy-4H-chromen-4-one (1). To a mixture
of morin (3.3 mmol) and K2CO3 (33 mmol) in acetone (20% DMF,100 mL) was slowly
added dimethyl sulfate (33 mmol) at room temperature. The mixture was stirred at room
temperature for 24 h. K2CO3 was filtered off and acetone was evaporated. The residue
was dissolved in EtOAc and washed with H2O and brine and dried over MgSO4. The
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product was purified by column chromatography (20 % EtOAc in hexane) to give a pale
yellow solid (90%). 1H NMR (500 MHz, CDCl3); δ 12.67 (s, 1H), 7.36 (d, 1H, J = 8.5),
6.58 (m, 2H), 6.34 (m, 2H), 3.87 (s, 3H), 3. 84 (s, 3H), 3.83 (s, 3H), 3.77 (s, 3H). 13C
NMR; δ 178.7, 165.2, 162.9, 162.0, 158.7, 157.4, 156.4, 140.0, 131.6, 112.4, 106.5,
104.7, 98.8, 97.7, 92.1, 60.5, 55.7, 55.5.
6,8-dibromo-2-(2,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy-4H-chromen-4-one (2).
To a solution of a methylated morin (0.28 mmol) in CH2Cl2 was added NBS (0.28 mmol)
at room temperature. The mixture was stirred at room temperature for 18 h. Additional
NBS (0.28 mmol) was added and stirred for 5 h. The reaction was washed with water
and brine. The organic phase was dried over MgSO4 and concentrated. Flash
chromatography (25 % EtOAc in hexane) was performed on silica gel to give a yellow
solid (41%). 1H NMR (500 MHz, CDCl3); δ 13.59 (s, 1H), 7.47 (d, 1H, J = 8.0), 6.58 (m,
2H), 3.96 (s, 3H), 3. 87 (s, 3H), 3.86 (s, 3H), 3.80 (s, 3H). 13C NMR; δ 178.2, 163.4,
159.5, 159.0, 157.77, 157.7, 151.9, 139.9, 131.9, 111.4, 109.3, 104.9, 100.1, 98.8, 95.1,
61.0, 60.4, 55.6, 55.5.
6,8-dibromo-2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one (Dibromomorin). The mixture of pyridine hydrochloride (30 eq.) and a compound 2 (0.096 mmol)
was heated to 150-160 °C for 4 h with stirring. The reaction was cooled to room
temperature, acidified by 1 M HCl and extracted with EtOAc. The organic phase was
washed with water and brine and dried over MgSO4. The crude product was purified by
column chromatography (silica gel, 10-20% MeOH in CH2Cl2) to give a yellow solid
(32%). LC-MS (C15H8Br2O7); [M+2] calc. 460, found 460. 1H NMR (500 MHz, DMSO-d6);
δ 13.49 (s, 1H), 12.75 (s, 1H), 7.63 (d, 1H, J = 2.0), 6.68 (m, 2H). 13C NMR; δ 176.8,
163.2, 159.9, 159.2, 157.7, 157.2, 150.8, 138.7, 132.4, 110.4, 108.3, 103.9, 99.1, 98.2,
94.9.128
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Morin Nanoparticle Synthesis and Concentration Quantitation
MNP was synthesized through the use of a synthetic polymer to surround and
encapsulate morin. Morin in water was intimately mixed with p407 polymer. The solution
was sonicated and put through a high pressure homogenizer to produce a homogenous
mixture of particle sizes. MNP size was analyzed via Dynamic Light Scattering. Morin
(MP biomedicals) used as standard, dissolved in methanol. MNP was centrifuged for 20
minutes at 20,000 RPM 4˚C, supernatant was removed, and methanol was used to
resuspend. The concentration of morin in the MNP was determined by a morin standard
dissolved in methanol. Serial dilutions were added to 96 well plate and absorbance (360
nm) measured using a BioTek scanner.128
MTT Cellular Toxicity
Cerebellar neurons were cultured in 96-well plates as previously described.34,37 At day 5,
neurons were treated for 24 hours with varying concentrations of morin derivatives (10
µM – 250 µM) to determine cellular toxicity of the compounds. After 24 hours, media was
removed and wells were washed with PBS. MTT was added to each well (0.5 mg/mL)
and incubated at 37˚C for one hour. DMSO was added to the wells, and plate was
placed on a shaking incubator for 30 minutes. Absorbance (570 nm) of MTT was
measured using BioTek scanner (Winooski, VT).128
SDS-PAGE Western Blot
Media was removed from 6-well plates and wells were washed with ice cold PBS. RIPA
buffer (25 mM tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Na deoxycholate, 1%
triton x-100, 3% glycerol) with protease and phosphatase inhibitors (Thermo-Fisher)
were added to each well and rocked on ice for 15 minutes. Cells were scraped from the
well, briefly sonicated, and centrifuged at 15,000 RPM for 10 minutes. The supernatant
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was removed. Protein concentration was quantified using a Pierce BCA assay (Thermo
Fisher) to ensure equal loading. Cell lysate, b-Me, and lamelli dye were heated at 90 C
for 5 minutes. Lysates were loaded into a 4-20% PAGE SDS gel (BioRad), and run at
100 V for 40 minutes. The gels were removed and washed, and transferred onto a PVDF
membrane at 75 V for 2 hours. Blots were washed with TBST, and blocked for one hour
at RT in TBST containing 5% bovine serum albumin. Blots were washed and conjugated
with primary antibody (directed towards: Glo-1, Glo-2, Nrf2, HO-1, IkB-a, P-IKK, IKKa/ß,
ß-actin) in 5% BSA, rocking overnight at 4˚C. Blots were washed with TBST, and
conjugated with appropriate secondary antibodies in TBST containing 5% BSA for one
hour at room temperature. Blots were washed and imaged using Western Dura Super
Signal (Thermo Fisher) on an Azure C600 imager (Azure Biosystems, Dublin, CA).
Densiometric analysis was performed with ImageJ (Madison, WI).128
ROS Detection
Cerebellar primary neurons were cultured in 96-well plates as previously described.180
Cells were treated with morin, DBM, or MNP [10 µM] for 24 hours, and then additionally
treated with MG [500 µM] for 24 hours. Media was removed, cells were washed with
PBS, and incubated with 1 µM CM-H2DCF-DA (Life Technology) in EBSS in dark at 37
˚C for 30 minutes. Fluorescence was recorded at 485 nm excitation and 520 nm
emission on a BioTek scanner.128
Immunocytochemistry
Cerebellar primary neurons were cultured in 96-well plates as previously described,34,37
Cells were treated with MG [500 µM] for 24 hours, and then additionally treated with
morin, DBM, or MNP [10 µM] for 24 hours,. Media was removed, wells were washed with
PBS, cells were fixed for 30 minutes with a 30% sucrose solution containing 4% PFA,
and washed. Cells were solubilized for 10 minutes with PBS containing 0.1% Triton X-
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100, and washed with PBS. Cells were blocked for 1 hour at room temperature with PBS
containing 2% BSA. Blocking solution was removed, and cells incubated overnight at
4˚C with PBS containing 2% BSA and primary antibodies directed towards NeuN,
cleaved caspase-3, VGLUT1, GAD65, and MAP2. Wells were washed with PBS and
incubated with the appropriate fluorescent conjugated secondary antibodies at room
temperature for 1 hour. Wells were washed, covered with DAPI stain [1 µg/mL] for 10
seconds, washed and aspirated. Prolong Gold Antifade (Thermo Fisher Scientific, MO)
was added directly to each well, and allowed to cure in the dark overnight. Plates were
imaged on CLS Operetta confocal microscope (PerkinElmer, Waltham MA). Statistical
analysis was performed through quantification of fluorescence normalized to the number
of DAPI positive cells.128
Glyoxalase Activity
Cerebellar primary neurons were cultured in 12-well plates as previously described, 34,37
After MG and morin derivative treatment, media was removed, and cells rinsed with
PBS. Cells were lysed with buffer (10 mM HEPES, 0.02% Triton X-100, and 100 μg/mL
BSA), briefly sonicated, and centrifuged. Reaction solution (60 mM sodium phosphate, 4
mM GSH, and 4 mM MG) in a 96 well plate was briefly incubated, followed by addition of
cell lysates. S-lactoylglutathione synthesis was determined by measuring absorbance
(240 nm) on a BioTek scanner. Protein concentration was determined using a BCA
protein assay reagent kit.128
D-Lactate Concentration
D-Lactate released into the extracellular space was measured spectrophotometrically
using collected cell media.34,37 Culture media samples were loaded on a 96-well plate
with 0.2 M glycine and semicarbazide buffer containing 2 mg/mL NAD and 40 U/mL Dlactate dehydrogenase. Samples were incubated at room temperature for 2 hours. A
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spectrophotometer (340 nm excitation, 450 nm emission) was used to measure
conversion of NAD to NADH. Absolute values were determined from a standard curve of
D-lactate concentrations.128
Methylglyoxal Concentration
MG concentration in cerebellar neuron cultures was determined using
dinitrophenylhydrazine (2,4-DMNPH).34,169 The reaction consisted of 0.2 mM 2,4DMNPH with 1 mM MG and previously collected culture media. Samples were heated in
a thermomixer at 42 °C for 45 mins and 600 rpm. Spectrophotometer measurements
were performed at 432 nm, according to absorbance of MG-bis- 2,4-DMNPH-hydrazone
for calculating concentration of MG.128
Caenorhabditis Elegans Strains and Maintenance
Caenorhabditis elegans (C. elegans) were cultured as previously described.181 C.
elegans were maintained on nematode growth medium (NGM) plates [Bacto Agar 1.7%,
Bacto Tryptone 0.25%, NaCl 50 mM, KPO4 25 mM, CaCl2 1 mM, MgSO4 1 mM, and
cholesterol 5 µg/mL], or in liquid S media [5.85 g NaCl, 1 g K2HPO4, 6 g KH2PO4, 1 ml
cholesterol (5 mg/ml), 10 ml 1 M potassium citrate pH 6, 10 ml trace metals solution, 3
ml 1 M CaCl2, 3 ml 1 M MgSO4] at 20 Cº. A single colony of E. coli OP50 was cultured in
LB media to OD 0.1, and 100 µL of was spread on NGM plates and incubated overnight
at 37 ºC. Synchronous L1 nematodes were added to NGM plates for experiments. C.
elegans cultures were washed and collected from starved NGM plates, and added
biweekly to fresh NGM plates with OP50.128
Culture Synchronicity
Synchronous populations of L1 C. elegans were obtained by bleaching as previously
described.181 NGM plates were washed with M9 media, and cultures collected for
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centrifugation (200 g, 2 min at 25ºC). The supernatant was removed, pellet washed with
M9 media, and recentrifuged. After removing supernatant, 2 mL of a bleaching solution
(2 mL of 8% bleach, 200 µL of 10M NaOH , and 8 mL H2O) was added for 7 minutes,
with gentle agitation every minute. Cultures were checked under a microscope to ensure
all adult worms died. M9 media was added to cultures to stop the reaction. The solution
was centrifuged (400 gx3 mins at 25º), supernatant removed, pellet washed, and
recentrifuged. The eggs were resuspended in S media, and allowed to gently rock for 24
hours until eggs hatched. An equal amount of L1 nematodes were added to plates with
M9 media for culturing. 5-Fluoro-2'-deoxyuridine (FUdR) was added to cultures on the
first day of adulthood to sterilize and prevent egg laying of gravid adults.128
Morin Derivative Treatment
Morin derivatives were dissolved in DMSO at a final concentration of 0.1%, and added to
freshly poured NGM plates at a concentration of 100 µM. MG was added directly to
freshly poured NGM plates at a concentration of 1 mM. All NGM plates contained FUdR
[250 µM] to prevent egg laying. Age synchronized L4 C. elegans were added to NGM
drug treatment plates that were changed biweekly.128
Statistics
All experiments were performed in triplicate, with values are presented as the mean +/SEM. Significance was determined by Student t-test, with p<0.05 being statistically
significant. # denotes statistical significance between the non MG-treated control and
MG-treated control; * denotes statistical significance between the MG-treated morin
derivatives and MG-treated control; + denotes statistical significance between non MGtreated control and non MG-treated morin derivatives; & denotes statistical significance
between morin and morin derivatives. Data were evaluated using Excel and SPSS.128
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RESULTS
Synthesis of DBM and MNP
DBM was synthesized through
a series of reactions involving
protection, bromination and
deprotection of morin (FIG 31A). Molecular structure was
confirmed through 1H-NMR and
MS/MS analysis (FIG 3-1B).
Nanoparticles are small
particles (less than 1000 nm)
composed of an active
chemical compound
encapsulated in a polymer in a
colloid solution.182,183
Characterization of the MNP
occurred through dynamic light

FIGURE 3-1: SYNTHESIS OF DBM.

scattering (DLS) to determine

DBM was synthesized from morin (A), and identified
through 1H-NMR (B).

the size, polar surface area,

and charge distribution. The size was determined to be ~415 nm with PDI 0.4, indicating
a homogenous concentration of nanoparticles. The concentration of morin encapsulated
in the nanoparticle was determined to be 3 mM, or 80%, by comparison with a standard
curve of morin concentrations.
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Toxicity of Morin Derivatives

FIGURE 3-2: TOXICITY OF MORIN DERIVATIVES.
The toxicity of morin derivatives were determined through an MTT assay. Cultured
neurons were treated with a range of doses [0-250 µM] of morin, DBM, and MNP.
Survival was determined 24 hours after treatment.

An MTT assay was performed in cerebellar neurons to determine the toxicity of morin,
DBM, MNP (FIG 3-2). All morin compounds exhibited low toxicity at concentrations up to
100 µM, and only the MNP exhibited significant toxicity only at extremely high doses
[250 µM].128 We determined the appropriate treatment condition to be 10 µM.
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Morin derivatives increase GP function and detoxification of MG

FIGURE 3-3: GP AND ANTIOXIDANT FUNCTION IN CEREBELLAR NEURONS.
Morin derivative treatments on MG (A), D-lactate (B), Glo-1 protein activity (measured in mU/µg
protein) (C), ROS production (D), and GSH (E). Results are the mean +/- SEM of experiments
performed in triplicate. #p<0.05, ##p<0.01, control compared to the MG-treated control; *p<0.05,
**p<0.01 morin derivative and MG-treated compared to MG treated control; +p<0.05 morin derivative
treated compared to non MG-treated control.

Addition of MG to cerebellar neuron cultures resulted in significant elevation of MG
(#p<0.05) compared to the control, however morin, DBM, and MNP significantly (*p<0.05)
decreased the concentration of MG compared to the MG treated control (Figure 3-3A).
Treatment with MG significantly (#<0.05) elevated D-lactate concentration compared to
the control, similarly morin, DBM, and MNP significantly (*p<0.05) elevated the
concentration of D-lactate compared to the MG treated control (Figure 3-3B). The
production of ROS was significantly (##p<0.01) increased by treatment with MG compared
to the control, but morin, DBM, and MNP significantly (**p<0.01) reduced the production
of ROS compared to the MG treated control (Figure 3-3C). The activity of Glo-1 (mU/µg)
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was significantly (*p<0.05) elevated in MG insulted cells treated with morin, DBM, and
MNP compared to the MG treated control (Figure 3-3D). Cerebellar neurons insulted with
MG exhibited significantly decreased GSH (#p<0.05) compared to the control, and
treatment with morin, DBM, and MNP significantly (*p<0.05) elevated the concentration of
GSH compared to the MG-treated control (Figure 3-3E). In the non-MG treated conditions,
morin, DBM, and MNP significantly (*p<0.05) elevated GSH compared to the control.
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Morin derivatives increase expression of glyoxalase pathway proteins

FIGURE 3-4: PROTEIN EXPRESSION IN CEREBELLAR NEURONS.
Morin derivative treatments in expression of Glo-1 (A) and Glo-2 (B); Nrf2 (C) and HO-1 (D); IKKa
(E), p-IKKa (F), and IκBa (G). Images are from representative Western blots. Results are the mean
+/- SEM of experiments performed in triplicate. #p<0.05, ##p<0.01, control compared to MG treated
control; *p<0.05, **p<0.01 morin derivative and MG treated compared to MG treated control; +p<0.05
morin derivative treated compared to control. &p<0.05 DBM compared to morin.

Cerebellar neurons insulted with MG had significantly (#p<0.05) lowered expression of
Glo-1 compared to the control, while treatment with morin, DBM, and MNP significantly
(*p<0.05) elevated expression of Glo-1 in MG insulted cells (Figure 3-4A). MG treatment
significantly (#p<0.05) reduced expression of Glo-2 compared to the control, while
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treatment with morin, DBM, and MNP significantly (*p<0.05) elevated expression of Glo-2
in MG insulted cells (Figure 3-4B).
Morin derivatives increase expression of antioxidant proteins
Cells produce cytoprotective proteins in response to elevated OS to counteract the
presence of inflammatory compounds. Nrf2 is a primary protein involved in antioxidant
response, and It functions as a transcription factor interacting with the antioxidant
response element (ARE) to induce the expression of other cytoprotective proteins. Hemeoxygenase-1 (HO-1) is another protein involved in antioxidant response that is expressed
under states of OS to prevent the accumulation and damaging effects of inflammatory
compounds. In MG insulted cells, treatment with morin, DBM, and MNP significantly
(**p<0.01) elevated the expression of both Nrf2 (Figure 3-4C) and HO-1 (Figure 3-4D).
Cells insulted with MG exhibit activation of antioxidant response, including expression of
Nrf2 (Figure 3-4C). Morin, DBM, and MNP significantly (*p<0.05, **p<0.01) elevated the
expression of Nrf2 and HO-1.
Morin derivatives inhibited activation of NF-kB signaling pathway
Activation of NF-kB causes its translocation to the nucleus, where it functions as a
transcription factor for the expression of apoptotic proteins.123,152,161 In its inactive form, it
is bound in the cytoplasm to the IkBa complex.123,152,161 Continued interaction with IkBa
protein IKKa causes NF-kB to be retained in the cytoplasm and degraded.

123,152,161

MG

treatment significantly elevated P-IKKa (*p<0.05) compared to the control (Figure 3-4F).
We observed a significant decrease in P-IKKa in MG insulted cells upon treatment with
morin(*p<0.05), DBM(*p<0.05), and MNP(*p<0.05). There was a significant increase in
IkBa in MG insulted cells treated with morin(*p<0.05), DBM(*p<0.01), and MNP(*p<0.05)
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compared to the MG treated control, and a significant increase upon treatment with DBM
(&<0.05) compared to morin (Figure 3-4G).
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Morin derivatives prevent MG-mediated caspase activation and apoptosis

FIGURE 3-5: APOPTOSIS IN CEREBELLAR NEURONS.
Morin derivative treatments in MG insulted cells measured by the percentage of cleaved caspase-3
positive cells (B). Representative images are shown (A). Results are the mean +/- SEM of
experiments performed in triplicate. #p<0.05, ##p<0.01, control compared to MG-treated control;
*p<0.05, **p<0.01 MG treated control compared to MG treated morin derivatives, &p<0.05 DBM
compared to morin.

NF-kB pathway mediated apoptosis occurs with the activation of cell death caspases.
Activation of caspase-3 causes it to be cleaved, inducing a signaling cascade that results
in apoptosis. Addition of MG to cerebellar neuron cultures lead to a significant (##p<0.01)
increase in the amount of cleaved caspase-3 positive cells (FIG 3-5). In MG insulted cells,
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we witnessed significant decrease in caspase positive cells with treatment of morin
(*p<0.05), DBM (**p<0.01), and MNP (*p<0.05). There was a significant decrease in
cleaved caspase-3 positive cells in treatment with DBM (&<0.05) compared to morin.
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Morin derivative treated neurons retained inhibitory neurotransmitter function

FIGURE 3-6: INHIBITORY NEUROTRANSMITTER FUNCTION.
Representative confocal images (A) and graphs of morin derivative treatments in MG
insulted neurons of GAD65 (B). Results are the mean +/- SEM of experiments
performed in triplicate. Fluorescence was normalized to amount of DAPI positive cells,
with representative images shown. #p<0.05, ##p<0.01, control compared to MG treated
control; *p<0.05 significant difference between MG treated control and MG treated
morin derivatives.

GAD65 is the protein responsible for synthesis of GABA - the primary inhibitory
neurotransmitter- through decarboxylation of glutamic acid or glutamate. Cerebellar
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neurons insulted with MG exhibited significant decrease in GAD65 compared to the
control. MG insulted cells treated with morin exhibited significant elevation in GAD65
(*p<0.05), DBM significantly elevated GAD65 (*p<0.05), MNP significantly elevated
GAD65 (*p<0.05) (FIG 3-6B). Representative confocal images are shown (FIG 3-6A).
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Morin derivative treated neurons retained excitatory neurotransmitter function.

FIGURE 3-7: EXCITATORY NEUROTRANSMITTER FUNCTION.
Representative confocal images and graphs of morin derivative treatments in MG insulted
neurons of VGLUT. Results are the mean +/- SEM of experiments performed in triplicate.
Fluorescence was normalized to amount of DAPI positive cells, with representative images
shown. #p<0.05, ##p<0.01, control compared to MG treated control; *p<0.05, **p<0.01 MG
treated control compared to MG treated morin derivatives, &p<0.05 MNP compared to
morin.

VGLUT is the protein involved in glutamate transport from neural vesicles, it is
responsible for shuttling glutamate from neural synapses. Buildup of glutamate in
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neurons is cytotoxic and induces apoptosis, and expression of VGLUT allows for
glutamate to be transported from neurons. Cerebellar neurons insulted with MG
exhibited significant decrease in VGLUT (FIG 3-7B) compared to the control. There was
a significant increase in VGLUT expression in MNP (&p<0.05) treated cells compared to
morin. Representative confocal images are shown (FIG 3-7A).
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Morin derivatives elevate expression of synaptic structural proteins.

FIGURE 3-8: SYNAPTIC STRUCTURAL PROTEIN EXPRESSION.
Representative confocal images (A) and graphs (B) of MAP2 in morin derivative
treatments in MG insulted neurons. Results are the mean +/- SEM of experiments
performed in triplicate. Fluorescence was normalized to amount of DAPI positive
cells, with representative images shown. #p<0.05, control compared to MG treated
control; *p<0.05, **p<0.01 MG treated control compared to MG treated morin
derivatives, &p<0.05 DBM and MNP compared to morin.

Microtubule-associated protein 2 (MAP2) is a structural protein involved in neurite and
dendritic branching, and is involved in interneuron signaling. Cerebellar neurons insulted
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with MG exhibited significant decrease in MAP2 (FIG 3-8B) compared to the control. MG
insulted cells treated with morin exhibited significant elevation in MAP2 (*p<0.05); DBM
significantly elevated MAP2 (*p<0.05); MNP significantly elevated MAP2 (*p<0.05). DBM
(&p<0.05) and MNP (&p<0.05) significantly increased MAP2 expression compared to
morin. Representative confocal images shown (FIG 3-8A) .

70
Morin derivatives extend lifespan of C. elegans

FIGURE 3-9: C. ELEGANS LIFESPAN EXTENSION.
Morin, DBM, and MNP were utilized to treat N2 (B), CL2006 (C), and VC343 (D) strains of
C. elegans, to determine the effect on lifespan. Morin, DBM, and MNP resulted in
significantly extended lifespans compared to the controls. Results are the mean +/- SEM of
experiments performed in at least triplicate. *p<0.05, **p<0.01 compared to control.

Morin, DBM, and MNP were utilized to treat C. elegans strains N2 (FIG 3-9B), CL2006
(AD model overexpressing Aβ, (FIG 3-9C), and VC343 (Glo-1 knockdown) (FIG 3-9D).
The average lifespan of morin treated C. elegans was significantly higher than the control
at days 17 (**p<0.01), 21 (**p<0.01), 25 (**p<0.01), and 29 (*p<0.05); The lifespan of DBM
treated C. elegans was significantly higher than the control at days 17(**p<0.01),
21(**p<0.01), 25(**p<0.01), and 29(**p<0.01); The lifespan of MNP treated C. elegans
was significantly higher than the control at days 17(**p<0.01), 21(**p<0.01), 25(**p<0.01),
and 29(*p<0.05).
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DISCUSSION
Proper functions of neural cells are heavily reliant upon GP detoxification of MG, to
prevent production of AGEs, ROS, and pro-inflammatory signaling molecules.20,21,97
Conversion of hemithioacetal to S,D-lactoylglutathione by Glo-1 is the rate limiting step
in the GP, and Glo-1 function is influenced by the expression levels of the protein and its
enzymatic activity.20,21,97 Therefore, modulating Glo-1 expression influences the activity
of the GP and impacts the levels of cellular OS and inflammation.20,21,97 Reducing Glo-1
expression results in elevated OS-mediated damage to cells and tissues. 44 Mice
transduced with Glo-1 siRNA showed accumulation of MG and AGEs in neural tissue,
and exhibited cognitive and behavioral dysfunction, and Glo-1 KO mice showed
significantly elevated concentrations of MG and AGEs.153 Glo-1 KO in mammalian
Schwann cells exhibited increased toxicity to MG and elevated levels of GSSG, with the
decrease in GSH/GSSH ratio corresponding to a decrease in Glo-1 activity, and
elevated MG and AGEs.45 Elevating Glo-1 through gene transduction reduced protein
and lipid glycation, and attenuated cognitive dysfunction in rats, and reduced markers of
apoptosis in H2O2 mediated OS in mouse hippocampal cells.48 42
The activity of flavonoids is influenced by structural characteristics, and antioxidant
activity was found to be highest in structures that contained: di-hydroxylated B ring, a C
ring containing a C2=C3 double bond and C4=O, and hydroxyl groups at C3 and C5.118
Morin and quercetin both contain all these structures, and performed better as
antioxidants than flavonoids naringenin and pinocembrin, which lack a C2=C3 bond.118
The only structural variation between quercetin and morin is the configuration of -OH
groups on the C ring, with quercetin possessing a 3’, 4’ configuration instead of the 2’, 4’
in morin.118 Flavonols are distinguished from other flavonoids by containing a C2=C3
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bond, 4C=O keto group, and a hydroxyl group at C3.184 A critical aspect of antioxidant
activity is influenced by the number and position of -OH groups; flavonol -OH groups aid
in binding interactions and stabilization with proteins and nucleic acids.185 Flavonoids
function as direct anti-AD agents through their ability to bind and prevent the fibrillation
of Ab proteins.119 Destabilizing the amyloid fibrils can disrupt their aggregation into Ab
plaques, leading to decreased toxicity and elevated clearance.119 The effectiveness of
Ab fibrilization inhibition was influenced by the ketone structure, and the presence of
hydroxyl groups - with dihydroxy structures more effective than monohydroxy.184184,185
Chemical substitutions at the site of -OH drastically reduced inhibition activity. 184184,185
Flavonol morin exhibited anti-Ab activity by binding to amyloid fibrils and reducing the
rate of polymerization.119 The bioavailability of flavonols – mediated by the presence and
position of hydroxyl groups - allows for penetration through the BBB to reach critical
areas of the brain where Ab formation occurs.119 The mechanism of flavonol interaction
with Ab occurs through hydrogen bonding of flavonol hydroxyl and carbonyl groups with
the amine groups present on Ab peptides.119 These interactions disrupt the peptide
structure of Ab, preventing the formation of a-helices and b-sheets present in Ab
plaques.119 Therefore, the presence of multiple hydroxyl groups on flavonols makes
them more adept at interaction and disruption of the Ab structure.119,184 An increasing
molar ratio of flavonol morin to Ab resulted in a change of the tertiary structure of Ab,
caused by the intercalation of flavonols into the Ab structure.119
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In this report we show that morin derivatives are capable of increasing the activity of the
GP. During states of OS, the GP is activated and elevates the transcription and
expression of its constituent proteins.22,64 Cerebellar neurons insulted with MG and
treated with morin, DBM, and MNP exhibited significantly elevated levels of GSH, Glo-1,
and Glo-2 compared to the MG treated controls. Treatment with morin derivatives also
significantly elevated Glo-1 activity, indicative of efficient and continuous GP activation.
In agreement with this, morin derivative treated cells had low levels of MG and ROS, and
elevated D-lactate, evidence of robust GP activity. Accumulation of MG induces an
inflammatory response and apoptosis, causing the death of neural cells and dysfunction
of normal cellular processes.9,10,15 Cerebellar neurons treated with MG exhibited
impaired neurotransmitter function, VGLUT1 and GAD65 – markers of excitatory and
inhibitory neurotransmission, respectively – were reduced upon treatment with MG. In
MG-insulted cells treated with morin, DBM, and MNP, this loss of neurotransmitter
activity was attenuated. VGLUT functions to shuttle glutamate out of cell, and a
reduction in VGLUT results in cellular glutamate accumulation, causing excessive Ca+2
influx and apoptosis.5,23,55 GAD65 decarboxylates glutamic acid into GABA, and reduced
GAD65 causes a shift in the balance of excitatory and inhibitory neurotransmission,
which can lead to inflammation and apoptosis. 4,53,54 Morin derivatives were able to
effectively preserve both excitatory and inhibitory neurotransmitter function. MAP2 is a
structural membrane protein involved in outgrowth of neurites and dendritic branching,
and it is essential for growth and connectivity of the neural network. 4,53,54 MG treatment
significantly reduced expression of MAP2 in cerebellar neurons, but this reduction was
attenuated by treatment with morin, DBM, and MNP. Morin derivatives exhibited the
ability to retain neural growth and protect mechanisms of neural signaling even under
states of extreme OS. Nrf2 is the primary transcription factor that binds and activates
ARE, leading to the expression of antioxidant proteins including HO-1, GSH, Glo-1, and
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FIGURE 3-10: ACTIVATION OF NF-ΚB PATHWAY.
The NF-κB protein complex is bound in the cytoplasm by IκB. MG/ROS bind and activate IKK,
which phosphorylates IκB and targets it for degradation. NF-κB proteins are translocated to
the nucleus and induce gene transcription and protein expression.

Glo-2. 129,144,146 Under a state of MG-mediated OS, morin derivatives induced the
expression of cytoprotective proteins, significantly elevating expression of Nrf2 and HO-1
compared to cells only treated with MG. Treatment with morin, DBM, and MNP
significantly elevated the expression of Nrf2 and HO-1 compared to cells treated with
MG alone. The NF-κB pathway is activated in response to cellular stress, and induces
apoptosis (FIG 3-10). 123,152,161 Inactive NF-κB proteins are located in the cytoplasm,
where they are bound by IκB of the IKK complex. 123,152,161 High levels of inflammation
and OS trigger ROS and cytokines to bind and activate the IKK complex. 123,152,161 After
activation, IKK phosphorylates IKB and it is ubiquitinated and degraded, allowing NF-κB
to undergo nuclear translocation. 123,152,161 NF-κB interacts with transcription factors and
induces the expression of apoptotic proteins. 123,152,161 Treatment with MG increased the
production of ROS in cerebellar neurons, and significantly elevated the levels of p-IKKα.
These neurons also had a significant reduction in IκBα, indicating it was degraded, and
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subsequently unbound from NF-κB. The MG treated neurons exhibited significantly
elevated cleaved caspase-3 through immunocytometric analysis. Conversely, the
neurons treated with MG and morin derivatives had significantly lower levels of ROS,
and P-IKKα levels similar to the non-MG treated controls. Morin derivative treated
neurons also expressed IκBα levels significantly higher than the MG treated control. This
is evidence that the IκB complex is still bound to cytoplasmic NF-κB. The inactivation of
NF-κB is evidenced by the significantly lower cleaved caspase-3 found in the morin
derivative treated cells. These results indicate that morin’s anti-inflammatory and antiapoptotic mechanisms are mediated by activation of the cellular protective Nrf2, and
inhibiting the activation of the NF-κB signaling pathways.
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FIGURE 3-11: C. ELEGANS LIFECYCLE.
C. elegans must be separated from progeny for accurate measurement of lifespan.
Adult C. elegans plated on NGM lay eggs, and are collected. Washing in a bleach
solution kills the gravid adults. Eggs are added to NGM plates with FUdR to prevent
progeny, resulting in a population of age-synchronized worms, which are used for
lifespan analysis.

The use of model organisms for determining effect of anti-aging agents is an important
tool for elucidating the function of antioxidant ability.186 The use of an in vivo model
system of C. elegans is useful for aging studies because of their relative ease of ability
to culture, rapid propagation, and genetic homology to humans, and their short lifespan
makes them an ideal species to study diseases associated with aging (FIG 3-11). 186,187
Isolating adult worms from their progeny is important to properly evaluate changes in
lifespan and aging. We found that treatment of CL2006 with all three flavonoid
compounds lead to a significant increase in their lifespan. While we did not investigate
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the mechanism of lifespan extension, it is known that flavonoid treatments induce the
expression of antioxidant and cytoprotective proteins.30,186-188
To improve on the inherent antioxidant capacity of flavonoids, we utilized the versatility of
halogen bonding to synthesize a brominated morin derivative, and formulated a morin
encapsulated nanoparticle. Our hypothesis was confirmed, evidenced by the increased
ability of DBM and MNP - compared to the parent compound - to prevent MG-mediated
OS through enhancement of the neural GP. DBM and MNP treatment increased
detoxification of MG, evidenced through elevated expression of Glo-1 and Glo-2, and
increased Glo-1 protein activity. These results were in parallel to increased D-lactate and
reduced production of ROS. Neurons exhibited a reduction in caspase-mediated
apoptosis, retained both excitatory and inhibitory neurotransmitter function, and exhibited
increased dendritic branching. This elevated antioxidant activity was mediated by
activation of the Nrf2 pathway and suppression of apoptotic NFkB signaling. The lifespan
of DBM or MNP treated C. elegans (CL2006) was significantly higher than the untreated
control confirming their potential as CNS drug.
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CHAPTER 4: CANNABIDIOL ENHANCES NEURAL
GLYOXALASE PATHWAY AND IMPROVES LIFESPAN IN
C. ELEGANS
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INTRODUCTION
The effect of secondary plant metabolites
and naturally-produced compounds have
been targeted for AD therapeutics, with
recent focus on phytocannabinoids as
anti-AD agents.51,92,116,138,189-191
The Cannabis Sativa (C. sativa) plant
has been used for its medicinal
properties for thousands of years, and

FIGURE 4-1: CBD STRUCTURE.
The chemical structure of non-psychoactive
phytocannabinoid CBD.

recent scientific advances have
elucidated the mechanism of the plants’ chemical compounds.189-196 C. sativa produces
over 100 phytocannabinoids in addition to terpenes, flavonoids, and other polyphenols,
with these secondary plant metabolites possessing a range of biological activity,
including antioxidant, anti-inflammatory, and anti-apoptosis.189-191,194,195,197 Cannabidiol
(CBD) is one of the primary phytocannabinoids produced by the plant, and it possesses
a myriad of medical and therapeutic uses (FIG 4-1).154,195,198-205 CBD possesses
structural characteristics – similar to our previously investigated flavonoids - that impart it
with antioxidant activity, most importantly the linked heterocyclic rings and number and
position of hydroxyl groups.154,199,204
In this chapter, we are the first to investigate CBD’s influence on the GP. This chapter
also investigates the influence of CBD of glyoxalase 3 (Glo-3) – also known as DJ-1 – as
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FIGURE 4-2: GLYOXALASE PATHWAY PROTEINS.
The GP consists of sequential reactions that results in the detoxification of carbonyl
compounds primarily MG. Glo-1 and Glo-2 are involved in the GSH-mediated
nonenzymatic neutralization of MG. Protein Glo-3 is involved in direct detoxification of
MG in a GSH-independent manner.

an alternate mechanism of MG detoxification (FIG 4-2).206,207 While the function of Glo-1
and Glo-2 have been elucidated through our previous works, the effect of Glo-3 has not
been thoroughly investigated, however Glo-3 is thought to function during chronic states
of OS during which diminished levels of GSH prevent efficient activity of Glo-1 and Glo2.206 We hypothesize that CBD exerts GP enhancing activity mediated by modulation of
cellular signaling pathways, including Nrf2 and NF-kB. CBD is well documented as a
potent antioxidant compound, and we aimed to elucidate its anti-inflammatory
mechanism and function.154,197,199,202-204 We utilized multiple models of AD including
primary mouse cerebellar neurons and genetically modified C. elegans to investigate the
effect of CBD on the GP. We determined CBD - like other plant produced compounds is neuroprotective and induces an antioxidant response mediated by Nrf2, which causes
the expression of cytoprotective proteins and inhibits the activation of apoptotic NF-kB
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signaling. Through multiple models of MG-mediated OS in AD, utilizing in vitro cerebellar
mouse neurons and in vivo C. elegans, we investigate the effect of CBD on the GP.
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MATERIALS AND METHODS
Care and use of animals
Animal studies were approved and performed in accordance with the UNMC Institutional
Animal Care and Utilization Committee (IACUC). C57BL/6 mice breeding pairs were
obtained from The Jackson Laboratory (Bar Harbor, ME). C. elegans strains N2 (Bristol),
VC343 (glod-4(gk189)), and GRU102 (dvls2), VH725, and Escherichia coli OP50 were
purchased from the Caenorhabditis Genetics Center (CGC) at the University of Minnesota
(MN, USA).
Chemicals and compounds
CBD was purchased from Cayman Chemical Company (Ann Arbor, MI). Sodium D-lactate
was purchased from Santa Cruz Biotechnology (Dallas, TX). Lactate dehydrogenase was
purchased from US Biological (Salem, MA). Poly-D-lysine hydrobromide, β-nicotinamide
adenine

dinucleotide

hydrate,

methylglyoxal,

5-fluorodeoxyuridine,

and

2,4-

Dinitrophenylhydrazine were purchased from Sigma Aldrich (St. Louis, MO). Antibodies
used were B-Actin (sc-47778), MAP-2 (sc-32791), caspase-3 p17 (sc-373730), HO-1 (sc390991), GAD-65 (sc-377145), Nrf2 (sc-81342), Glyoxalase I (sc-133214), Glyoxalase II
(sc-166781), m-IgGk BP-HRP (sc-516102), m-IgGk BP-CFL 488 (sc-516176), m-IgGk
BP-CFL 555 (sc-516177) from Santa Cruz Biotechnology (Dallas, TX); DJ-1 (5933), P-Akt
(4060), IKKa (11930S), IkBa (4812S), P- IKKa (2697S) from Cell Signaling Technology
(Danvers, MA); VGLUT1 (AB5905), NeuN (MAB377) EMD Millipore (Temecula, CA).
Unless otherwise noted, chemicals for this study were purchased from Thermo Fisher
Scientific (Fair Lawn, NJ).
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Primary Cell Culture
Cerebellar neurons were harvested from P3 C57/BL6 (Jackson Labs) as previously
described. Corning plates were left under UV light for 30 mins, and poly-D-lysine HBr (MP
Biomedicals) was added to wells (150 µg/mL) for 3 hours. Wells were washed three times
with endonuclease-free water. The brains were removed via cervical dissection. The
cerebellum was isolated, and the veins and meninges were removed. The tissue was
treated with 2.5% trypsin for 15 minutes. The trypsin was removed, and 1%
deoxyribonuclease was added and tissue was pipetted gently to form a homogenous
mixture. Cells were centrifuged at 700 x g for 5 minutes. The supernatant was removed,
and 1% DNase was added and resuspended. The solution was then filtered through a 40
µm nylon screen and centrifuged at 700 x g for 5 minutes. The supernatant was removed,
and the pellet resuspended in BME serum media (Fetal Bovine serum, horse serum,
glucose, glutamine). Cells were counted using a hemocytometer and seeded onto 6-well
plates (1.5x106 cells/well), 12-well plates (5×105 cells/well), or 96-well plates (5x104
cells/well). Media were changed into serum-free DMEM (B27, N2, sucrose, glutamine,
PS) after 4 hours. AraC was added (5 µM) after 24 hours to ensure a homogenous neural
culture. Cells were incubated at 37˚C (5% CO2) with half media changes every 2 days.
Confluent cultures on day 5 were treated with MG (500 µM) and flavonoid (10 µM), or
vehicle (0.1% DMSO) for 24 hours. Media and lysates were collected and stored at -80˚C.
MTT cellular toxicity
Cerebellar neurons were cultured in 96-well plates as previously described. At day 5,
neurons were treated for 24 hours with varying concentrations of CBD (10 µM – 250 µM)
to determine cellular toxicity of the compounds. After 24 hours, media was removed and
wells were washed with PBS. MTT was added to each well (0.5 mg/mL) and incubated at
37˚C for one hour. DMSO was added to the wells, and plate was placed on a shaking
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incubator for 30 minutes. Absorbance (570 nm) of MTT was measured using BioTek
scanner (Winooski, VT).
SDS-PAGE Western Blot
Media was removed from 6-well plates and wells were washed with ice cold PBS. RIPA
buffer (25 mM tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Na deoxycholate, 1% triton
x-100, 3% glycerol) with protease and phosphatase inhibitors (Thermo-Fisher) were
added to each well and rocked on ice for 15 minutes. Cells were scraped from the well,
briefly sonicated, and centrifuged at 15,000 RPM for 10 minutes. The supernatant was
removed. Protein concentration was quantified using a Pierce BCA assay (Thermo Fisher)
to ensure equal loading. Cell lysate, b-Me, and lamelli dye were heated at 90 C for 5
minutes. Lysates were loaded into a 4-20% PAGE SDS gel (BioRad), and run at 100 V for
40 minutes. The gels were removed and washed, and transferred onto a PVDF membrane
at 75 V for 2 hours. Blots were washed with TBST, and blocked for one hour at RT in
TBST containing 5% bovine serum albumin. Blots were washed and conjugated with
primary antibody (directed towards: Glo-1, Glo-2, Nrf2, HO-1, IkB-a, P-IKK, IKKa/ß, ßactin) in 5% BSA, rocking overnight at 4˚C. Blots were washed with TBST, and conjugated
with appropriate secondary antibodies in TBST containing 5% BSA for one hour at room
temperature. Blots were washed and imaged using Western Dura Super Signal (Thermo
Fisher) on an Azure C600 imager (Azure Biosystems, Dublin, CA). Densiometric analysis
was performed with ImageJ (Madison, WI).
ROS detection
Cerebellar primary neurons were cultured in 96-well plates as previously described. Cells
were treated with CBD [10 µM] for 24 hours, and then additionally treated with MG [500
µM] for 24 hours. Media was removed, cells were washed with PBS, and incubated with
1 µM CM-H2DCF-DA (Life Technology) in EBSS in dark at 37 ˚C for 30 minutes.
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Fluorescence was recorded at 485 nm excitation and 520 nm emission on a BioTek
scanner.
Immunocytochemistry
Cerebellar primary neurons were cultured in 96-well plates as previously described. Cells
were treated with MG [500 µM] for 24 hours, and then additionally treated with CBD [10
µM] for 24 hours. Media was removed, wells were washed with PBS, cells were fixed for
30 minutes with a 30% sucrose solution containing 4% PFA, and washed. Cells were
solubilized for 10 minutes with PBS containing 0.1% Triton X-100, and washed with PBS.
Cells were blocked for 1 hour at room temperature with PBS containing 2% BSA. Blocking
solution was removed, and cells incubated overnight at 4˚C with PBS containing 2% BSA
and primary antibodies directed towards NeuN, cleaved caspase-3, VGLUT1, GAD65, and
MAP2. Wells were washed with PBS and incubated with the appropriate fluorescent
conjugated secondary antibodies at room temperature for 1 hour. Wells were washed,
covered with DAPI stain [1 µg/mL] for 10 seconds, washed and aspirated. Prolong Gold
Antifade (Thermo Fisher Scientific, MO) was added directly to each well, and allowed to
cure in the dark overnight. Plates were imaged on CLS Operetta confocal microscope
(PerkinElmer, Waltham MA). Statistical analysis was performed through quantification of
fluorescence normalized to the number of DAPI positive cells.
Glyoxalase activity
Cerebellar primary neurons were cultured in 12-well plates as previously described. After
MG and CBD treatment, media was removed, and cells rinsed with PBS. Cells were lysed
with buffer (10 mM HEPES, 0.02% Triton X-100, and 100 μg/mL BSA), briefly sonicated,
and centrifuged. Reaction solution (60 mM sodium phosphate, 4 mM GSH, and 4 mM MG)
in a 96 well plate was briefly incubated, followed by addition of cell lysates. Slactoylglutathione synthesis was determined by measuring absorbance (240 nm) on a
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BioTek scanner. Protein concentration was determined using a BCA protein assay reagent
kit.
D-Lactate concentration
D-Lactate released into the extracellular space was measured spectrophotometrically
using collected cell media. Culture media samples were loaded on a 96-well plate with 0.2
M glycine and semicarbazide buffer containing 2 mg/mL NAD and 40 U/mL D-lactate
dehydrogenase. Samples were incubated at room temperature for 2 hours. A
spectrophotometer (340 nm excitation, 450 nm emission) was used to measure
conversion of NAD to NADH. Absolute values were determined from a standard curve of
D-lactate concentrations.
MG concentration
MG concentration in cerebellar neuron cultures was determined using
dinitrophenylhydrazine (2,4-DNPH). The reaction consisted of 0.2 mM 2,4-DNPH with 1
mM MG and previously collected culture media. Samples were heated in a thermomixer
at 42 °C for 45 mins and 600 rpm. Spectrophotometer measurements were performed at
432 nm, according to absorbance of MG-bis- 2,4-DNPH-hydrazone for calculating
concentration of MG.
C. elegans strains and maintenance
C. elegans were cultured as previously described. C. elegans were maintained on
nematode growth medium (NGM) plates [Bacto Agar 1.7%, Bacto Tryptone 0.25%, NaCl
50 mM, KPO4 25 mM, CaCl2 1 mM, MgSO4 1 mM, and cholesterol 5 µg/mL], or in liquid S
media [5.85 g NaCl, 1 g K2HPO4, 6 g KH2PO4, 1 ml cholesterol (5 mg/ml), 10 ml 1 M
potassium citrate pH 6, 10 ml trace metals solution, 3 ml 1 M CaCl2, 3 ml 1 M MgSO4] at
20 Cº. A single colony of E. coli OP50 was cultured in LB media to OD 0.1, and 100 µL of
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was spread on NGM plates and incubated overnight at 37 ºC. Synchronous L1 nematodes
were added to NGM plates for experiments. C. elegans cultures were washed and
collected from starved NGM plates, and added biweekly to fresh NGM plates with OP50.
Culture synchronicity
Synchronous populations of L1 C. elegans were obtained by bleaching as previously
described.

NGM plates were washed with M9 media, and cultures collected for

centrifugation (200 g, 2 min at 25ºC). The supernatant was removed, pellet washed with
M9 media, and recentrifuged. After removing supernatant, 2 mL of a bleaching solution (2
mL of 8% bleach, 200 µL of 10M NaOH , and 8 mL H2O) was added for 7 minutes, with
gentle agitation every minute. Cultures were checked under a microscope to ensure all
adult worms died. M9 media was added to cultures to stop the reaction. The solution was
centrifuged (400 gx3 mins at 25º), supernatant removed, pellet washed, and recentrifuged.
The pellet of eggs was resuspended in S media, and allowed to gently rock for 24 hours
until eggs hatched. An equal amount of L1 nematodes were added to plates with M9 media
for culturing. 5-Fluoro-2'-deoxyuridine (FUdR) was added to cultures on the first day of
adulthood to sterilize and prevent egg laying of gravid adults.
C. elegans CBD Treatment
CBD was dissolved in DMSO at a final concentration of 0.1%, and added to freshly poured
NGM plates at a concentration of 100 µM. MG was added directly to freshly poured NGM
plates at a concentration of 500 µM. All NGM plates contained FUdR [250 µM] to prevent
egg laying. Age synchronized L4 C. elegans were added to NGM drug treatment plates
that were changed biweekly.

88
C. elegans thermotolerance
Nematodes were cultured to adulthood as previously described. Age synchronized adult
worms were transferred to fresh NGM plates and incubated at 35º C. Worms were
monitored every 2 hours to determine survival.
C. elegans OS resistance
Nematodes were cultured to adulthood as previously described. Adult nematodes were
transferred to 96 well plate with S-complete media, with varying concentrations of MG
[100, 250, 500, 750, 1000 µM]. Survival was monitored every day until all worms were
dead.
Statistics
All experiments were performed in triplicate, with values are presented as the mean +/SEM. Significance was determined by Student t-test, with p<0.05 being statistically
significant. # denotes statistical significance between the non MG-treated control and MGtreated control; * denotes statistical significance between the MG-treated and CBD treated
and MG-treated control; + denotes statistical significance between non MG-treated control
and non MG-treated CBD treatment. Data were evaluated using Excel and SPSS.
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RESULTS
CBD on Glyoxalase Pathway Function.

FIGURE 4-3: GP FUNCTION IN CEREBELLAR NEURONS.
CBD treatments on MG (A), D-lactate (B), ROS (C), Glo-1 protein activity (measured in
mU/µg protein) (D), and GSH (E). Results are the mean +/- SEM of experiments performed
in triplicate. #p<0.05, ##p<0.01, control compared to the MG-treated control; *p<0.05,
**p<0.01 CBD and MG-treated compared to MG treated control; &p<0.05 CBD treated
compared to control.

Cerebellar neurons treated insulted with MG and treated with CBD exhibited elevated
function and activity of GP. Neurons insulted with MG [500 µM] exhibited elevated levels
of MG compared to the non MG-treated control (# #p<0.01), which was significantly
decreased (**p<0.01) upon treatment with CBD (FIG 4-3A). In accordance with this, MG
treatment also resulted in elevated levels of D-lactate compared to the control
(##p<0.01; however, in MG and CBD treated neurons we witnessed a concomitant
elevation of D-lactate (**p<0.01), indicative of elevated MG detoxification (FIG 4-3B). We
observed a drastic elevation in production of ROS upon MG treatment (###p< 0.005),
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which CBD treatment significantly (**p<0.01) attenuated (FIG 4-3C). MG treatment is
known to elevate Glo-1 activity, as cells respond to the oxidative insult. CBD treatment in
non MG-treated cells significantly elevated Glo-1 activity compared to the control
(&p<0.05), and also lead to an increase in Glo-1 activity in MG and CBD treated cells
(*p<0.05) compared to the MG-treated control (FIG 4-3D). MG treatment depletes
intracellular GSH levels, which was attenuated by CBD treatment (*p<0.05), and CBD
treatment alone significantly elevated GSH levels (&p<0.05) compared to the non MGtreated controls (FIG 4-3E).
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CBD Elevates Glyoxalase Protein Expression

FIGURE 4-4: GLYOXALASE PROTEIN EXPRESSION.
Protein expression of Glo-1 (A), Glo-2 (B), and Glo-3 (C) in CBD and MG treated cerebellar
neurons was determined through Western blotting (D). Results are the mean +/- SEM of
experiments performed in triplicate. #p<0.05, ##p<0.01, control compared to the MG-treated
control; *p<0.05, **p<0.01 CBD and MG-treated compared to MG treated control; &p<0.05 CBD
treated compared to control.

Levels of glyoxalase protein expression in cerebellar neurons treated with MG and CBD
was determined through Western blotting (FIG 4-4D). Glo-1 protein expression (FIG 44A) was significantly decreased with MG treatment (#p<0.05), and significantly
increased with CBD treatment (&p<0.05) compared to the non-treated control. Treatment
with both MG and CBD resulted in a significant increase (*p<0.05) compared to the MG
treated cells. Glo-2 protein expression (FIG 4-4B) significantly decreased with MG
treatment (#p<0.05) compared to the control, however treatment with both MG and CBD
resulted in a significant increase (*p<0.05) in expression compared to the MG treated
cells. CBD treatment alone increased protein expression, but not to a level of statistical
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significance. DJ-1 – also known as glyoxalase 3 (Glo-3) – expression (FIG 4-4C) was
significantly elevated with CBD treatment (&p<0.05) compared to the non-treated
controls, and MG and CBD treatment resulted in a significant increase (*p<0.05)
compared to the MG treated control. Here, CBD increased the expression of Glo-1,2 and
3 compared to control. We did not observe significant changes in protein expression
upon MG treatment alone compared to the control.
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CBD increases antioxidant protein expression

FIGURE 4-5: ANTIOXIDANT PROTEIN EXPRESSION.
Protein expression of Nrf2 (A), HO-1 (B), and NQ01 (C) in CBD and MG treated
cerebellar neurons was determined through Western blotting (D). Results are the mean
+/- SEM of experiments performed in triplicate. ##p<0.01, control compared to the MGtreated control; *p<0.05, CBD and MG-treated compared to MG treated control; &p<0.05,
&&p<0.01 CBD treated compared to control.

Antioxidant protein expression levels in cerebellar neurons treated with MG and CBD
was determined through Western blotting (FIG 4-5D). Nrf2 protein expression (FIG 4-5A)
was significantly increased with CBD treatment (&p<0.05) compared to the non-treated
control. Treatment with both MG and CBD resulted in a significant increase (*p<0.05)
compared to the MG treated cells. HO-1 protein expression (FIG 4-5B) significantly
increased with MG treatment (##p<0.01) and CBD treatment (&&p<0.01) compared to
the non-treated control. NQO1 expression (FIG 4-5C) was significantly elevated with
CBD treatment (&p<0.05) compared to the non-treated controls, and MG and CBD
treatment resulted in a significant increase (*p<0.05) compared to the MG treated
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control. Overall CBD increased the expression of HO-1, Nrf2, and NQO1. However, the
effect is insensitive to MG treatment.
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CBD modulates p38 cellular signaling

FIGURE 4-6: CELLULAR SIGNALING PATHWAYS.
Protein expression of p38 (A) and P-p38 (B) in CBD and MG treated cerebellar neurons was
determined through Western blotting (C). Results are the mean +/- SEM of experiments
performed in triplicate. ##p<0.01, control compared to the MG-treated control; *p<0.05,
***p<0.005 CBD and MG-treated compared to MG treated control; &p<0.05, &&&p<0.005 CBD
treated compared to control.

Cellular signaling pathways in cerebellar neurons treated with MG and CBD was
determined through Western blotting (FIG 4-6C). p38 protein expression (FIG 4-6A) was
significantly increased with CBD treatment (&&&p<0.005) compared to the non-treated
control. Treatment with both MG and CBD resulted in a significant increase (***p<0.005)
compared to the MG treated cells. P-p38 protein expression (FIG 4-6B) was significantly
decreased with CBD treatment (&p<0.05) compared to the non-treated control, and
treatment with both MG and CBD resulted in a significant decrease (*p<0.05) compared
to the MG treated cells.
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CBD reduces SAPK/JNK activation

FIGURE 4-7: SAPK/JNK ACTIVATION.
Protein expression of P-SAPK/JNK (A) in CBD and MG treated cerebellar neurons was
determined through Western blotting (B). Results are the mean +/- SEM of
experiments performed in triplicate. ##p<0.01, control compared to the MG-treated
control. *p<0.05 CBD and MG-treated compared to MG-treated control.

Activation of the SAPK/JNK cellular signaling pathway in cerebellar neurons treated with
MG and CBD was determined through Western blotting (FIG 4-7B). Treatment with MG
resulted in a significant decrease (##p<0.01) in P-SAPK/JNK (FIG 4-7A) compared to
the nontreated control. Treatment with both MG and CBD resulted in a significant
decrease (*p<0.05) of SAPK/JNK phosphorylation compared to the MG treated control.
The CBD treatment also neutralized the effect of MG treatment on SAPK/JNK.
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CBD increases excitatory and inhibitory neurotransmitter function

FIGURE 4-8: CEREBELLAR NEURON NEUROTRANSMITTER FUNCTION.
Representative confocal images (A) of GAD65 (B) and VGLUT (C) expression in CBD and MG
treated cerebellar neurons. Results are the mean +/- SEM of experiments performed in triplicate.
#p<0.05 control compared to the MG-treated control; **p<0.01 CBD and MG-treated compared to
MG treated control; &p<0.05 CBD treated compared to control.

In cerebellar neurons insulted with MG [500 µM], treatment with CBD [10 µM] exhibited
neuroprotective activity and resulted in retention of neurotransmitter function in
cerebellar neurons (FIG 4-8A). Inhibitory neurotransmitter activity was determined
through measuring fluorescence expression of GAD65 (FIG 4-8B). Treatment with MG
resulted in a significant decrease (#p<0.05) of GAD65 expression compared to the
control. Treatment with CBD resulted in a significant increase (&p<0.05) of GAD65
compared to the control. Neurons treated with MG and CBD resulted in a significant
increase (**p<0.01) of GAD65 expression compared to the MG treated control.
Excitatory neurotransmitter activity was determined through measuring fluorescence
expression of VGLUT (FIG 4-8C). Treatment with MG resulted in a significant decrease
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(#p<0.05) of VGLUT expression compared to the control. Treatment with CBD resulted
in a significant increase (&p<0.05) of VGLUT expression compared to the control.
Treatment with both MG and CBD resulted in a significant increase (**p<0.01) of VGLUT
expression compared to the MG treated control.
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CBD increases C. elegans Lifespan

FIGURE 4-9: CBD INCREASES LIFESPAN IN C. ELEGANS.
CBD treatment increased lifespan and longevity in C. elegans strains N2 (A), VC343 (B),
VH725 (C), and GRU102 (D). Results are the mean +/- SEM of experiments performed
in triplicate. *p<0.05, **p<0.01 CBD treated compared to control.

C. elegans strains were treated with CBD [100 µM] and the effect on lifespan and
longevity was determined. There was a significant increase in survival at various
timepoints in different C. elegans strains: N2 (FIG 4-9A) exhibited elevated survival at
days 17 (*p<0.05), 21(**p<0.01), 25(**p<0.01), 29 (*p<0.05), and 33 (*p<0.05); VC343
(FIG 4-9B) 13 (*p<0.05), 17 (*p<0.05), 21(**p<0.01), 25(**p<0.01), and 29(**p<0.01);
VH725 (FIG 4-9C) 25 (*p<0.05), 29 (*p<0.05), 33 (*p<0.05), and 37 (*p<0.05); GRU102
(FIG 4-9D) 17 (*p<0.05), 21(**p<0.01), 25(**p<0.01), and 29 (**p<0.01).
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MG Treatment Reduces C. elegans Lifespan.

FIGURE 4-10: MG REDUCES C. ELEGANS LIFESPAN.
The effect of MG on lifespan of C. elegans strains N2 (A), VC343 (B), VH725 (C), GRU102
(D) was determined. Results are the mean +/- SEM of experiments performed in triplicate.
*p<0.05, **p<0.01 CBD treated compared to control.

The effect of MG treatment [1 mM] on C. elegans lifespan was determined. There was a
significant decrease in survival at various timepoints in different C. elegans strains: N2
(FIG 4-10A) 10 (*p<0.05), 15 (**p<0.01), 20 (**p<0.01), and 25 (***p<0.005), VC343
(FIG 4-10B) 12 (*p<0.05), 16 (**p<0.01), 20(**p<0.01), and 24(**p<0.01); VH725 (FIG 410C) 12 (**p<0.01), 16 (**p<0.01), 20 (**p<0.01), 24 (*p<0.05), and 28 (*p<0.05);
GRU102 (FIG 4-10D) 8 (*p<0.05), 12(**p<0.01), 16(**p<0.01), and 20 (*p<0.05).
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MG and CBD treatment on C. elegans Lifespan

FIGURE 4-11: CBD AND MG TREATMENT ON C. ELEGANS LIFESPAN.
All C. elegans strains exhibited a significant (*p<0.05) increase in average lifespan
compared to the MG treated C. elegans. Results are the mean +/- SEM of
experiments performed in triplicate.

The effect of combination treatment of CBD [100 µM] and MG [1 mM] on lifespan was
determined in C. elegans strains (FIG 4-11). While MG treatment alone significantly
reduced C. elegans lifespan, the combination treatment with CBD exhibited a protective
effect against MG toxicity. Compared to MG treatment alone, the combination treatment
resulted in significant (*p<0.05) lifespan increases in N2 (7 days), VC343 (6 days),
VH725 (6 days), and GRU102 (6 days).
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Oxidative Stress and Thermotolerance Resistance in C. elegans

FIGURE 4-12: OXIDATIVE STRESS AND THERMOTOLERANCE RESISTANCE IN C. ELEGANS.
Resistance to OS induced by H2O2 was measured in N2 (A), VC343 (B), VH725 (C), and
GRU102 (D). Thermotolerance was measured in N2 (E), VC343 (F), VH725 (G), and GRU102
(H). Results are the mean +/- SEM of experiments performed in triplicate. #p<0.05, ##p<0.01,
control compared to the MG-treated control; *p<0.05, **p<0.01 CBD and MG-treated
compared to MG treated control; &p<0.05 CBD treated compared to control.

C. elegans strains were treated with H2O2 to induce OS and treated with CBD [100 or
200 µM], MG [1 mM], or a combination. Results showed a significant decrease in
survival in MG treated C. elegans strains N2 (#p<0.05) (FIG 4-12A), VC343 (#p<0.05)
(FIG 4-12B), VH725 (##p<0.01) (FIG 4-12C), and GRU102 (#p<0.05) (FIG 4-12D). In all
strains of C. elegans, treatment with CBD lead to a significant increase in survival. There
was not significant survival determined between treatments of 100 or 200 µM CBD. Their
survival in the MG treated condition was miniscule, and significantly increased upon
treatment with CBD at 100 and 200 µM. The Glo-1 overexpressing strain VH725
exhibited significantly extended survival with CBD treatment, and significantly extended
survival in the CBD and MG combination treatment. The survival of N2 and VH725 C.
elegans was not significant.
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CBD Reduces Ab Expression in GRU102 C. elegans

FIGURE 4-13: Ab EXPRESSION IN GRU102 C. ELEGANS.
Representative confocal images (A) of GRU102 C. elegans treated with MG and CBD (B).
Results are the mean +/- SEM of experiments performed in triplicate. ###p<0.005, control
compared to the MG-treated control; **p<0.01 CBD and MG-treated compared to MG
treated control; &p<0.05 CBD treated compared to control.

Aβ expressing GRU102 C. elegans were treated with CBD [100 µM], MG [1 mM], or a
combination, and visualized through confocal microscopy (FIG 4-13A) to determine GFP
expression of Ab. CBD treatment reduced the fluorescence expression of Ab in mutated
C. elegans (FIG 4-13B). Insulting C. elegans with MG resulted in significantly elevated
GFP expression of Ab (###p<0.005), which was drastically reduced upon treatment with
CBD (**p<0.01). CBD treatment alone also lead to a significant reduction (&p<0.05) in
fluorescence expression in the control. MG treatment significantly increased expression
of Ab in GRU102 C. elegans. Treatment with CBD significantly lowered Ab expression,
and the combination treatment lowered Ab expression to levels indistinguishable from
the control group.
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DISCUSSION
While phytocannabinoids have been long utilized for their medicinal properties, their
exact mechanisms of pharmacological activity have only recently been
elucidated.190,191,208 Cannabinoids are separated into three groups: phytocannabinoids
produced by the C. sativa plant, endogenously produced endocannabinoids, and
synthetic cannabinoids.190 In addition to the over 100 identified phytocannabinoids, C.
sativa produces a host of other secondary metabolites including terpenes, sterols,
polyphenols, and flavonoids.189,193,209 These chemical compounds are synthesized
primarily in the flowers of the female plants, and secreted through the trichrome glands;
the leaves, stalks, and root matter also contain secondary metabolites, although in
significantly smaller concentrations.191,208,209 The most abundantly produced
phytocannabinoids are D9-tetrahydrocannabinol (THC) and CBD, with cannabigerol
(CBG), cannabinol (CBN), and cannabichromene (CBC) present in lower
concentrations.210,211 The phytocannabinoids are synthesized in the carboxylic acid form
in the plant, and must be decarboxylated and converted to the neutral form for
bioactivity.189,191,210 A large part of CBD’s utility stems from its lack of psychoactivity mediated through its low affinity for CB1 – unlike THC.190,212 CBD is a very durable and
pharmacologically valuable compound with antibacterial, antiviral, and anti-cancer
properties, in addition to its well documented antioxidant and anti-inflammatory
activity.190,213,214 It is neuroprotective in a variety of illnesses including epilepsy, ischemia,
MS, HD, PD, and AD.171,196,200,205,215-220 The mechanism of CBD’s neuroprotective activity
involves modulation of signaling molecules, suppressing inflammatory cytokines while
increasing production of anti-inflammatory cytokines and compounds.196,198,203,205,221 In an
experimental autoimmune encephalitis model of multiple sclerosis, CBD attenuated the
neuroinflammation mediated by autoreactive T cells.218 CBD is also able to modulate
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neuroinflammatory immune response by preventing overactivation of glial cells, a
common hallmark in neurodegenerative diseases.215,218,222-224 CBD treatment
downregulated gene transcription of pro-inflammatory cytokines (IL-17, IL-6, IL-1b, TNFa), while simultaneously upregulating gene transcription of anti-inflammatory cytokine IL10.218 In AD, CBD has shown evidence of multiple mechanisms of
neuroprotection.154,171,217 CBD was shown to attenuate Ab toxicity by reducing the
production of TNF-a, IL-1b, and NO through activation of PPAR-g and inactivation of NFkB. CBD is able to directly modulate the expression of AD pathology, through
ubiquitination of APP and reducing reactive Ab production.194
The activity and molecular effects of CBD are determined and mediated through the
structure activity relationship (SAR) of the chemical compound.189,190,212 Thus, the
specific composition and arrangement of CBD is inexorably linked to its
bioactivity.189,190,212 CBD is conferred its antioxidant activity through several structural
characteristics: hydroxyl groups of the B phenolic ring, the methyl group of the A
cyclohexene ring, and the pentyl side chain.190,194,212 The key structural features of
CBD’s antioxidant effects are the aromatic B ring hydroxyl groups.199,203,204 CBD exists in
several resonance structures, where unpaired electrons are located on the benzene ring
and alkyl side chains.225 This mediates direct antioxidant activity through proton transfer
and electron donation with ROS and other free radical molecules.192 The aromatic
hydroxyl groups also afford amino acid and nucleic acid binding ability.204 Both the
number and location of hydroxyl groups are essential for antioxidant activity.184,185,204
Although CBD and THC are structurally very similar, the CBD contains two hydroxyl
groups on the B ring compared to a single hydroxyl group of THC. 204,226 Consequently,
CBD was found to be a better free radical scavenger and have higher antioxidant activity
than THC. 226 The same structural characteristics that impart antioxidant activity in CBD
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are shared in flavonoid compounds (FIG
4-14). CBD and our previously utilized
flavonoids – catechin, morin, and
quercetin - possess similar carbon
backbone.19,184,185 The di-hydroxylation of
the B ring is an essential component of
antioxidant activity, which is shared by
CBD, morin, quercetin, and
catechin.118,184,185 However, the
arrangement of hydroxyl groups is an
important factor in activity. The meta
configuration of hydroxyls at 2’ and 6’ is
shared by both morin and CBD, while
quercetin and catechin possess an ortho
configuration of hydroxyls at 4’ and
5’.184,185,199 Flavonoids with a resorcinol
structure we found to have higher
antioxidant activity than either catechol or

FIGURE 4-14: STRUCTURAL SIMILARITIES OF CBD AND
MORIN.

The presence of multiple hydroxyl groups (blue),
heterocyclic rings with C=C (green), and 3-carbon
alcohol moieties (red) confer antioxidant activity in
both morin and CBD.

hydroquinone structures.51,119,120,163
Linked heterocyclic rings - including a phenol ring and C=C bond – confers chemical
activity and are present in CBD and flavonoids.118-120 Another consideration of activity is
the spatial arrangement of ring structures. Both CBD and morin possess rings (A and B,
respectively) that are in almost perpendicular planes, which influences binding
activity.19,116,120 For example, THC and flavonoid apigenin exist in a rigid, planar
configuration, and were determined to have decreased antioxidant activity compared to
CBD and non-planar flavonoids. 19,75,76,116,226 Direct redox regulation by CBD occurs
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through modulation of both pro and anti-oxidant molecules.199,203 CBD can bind ROS,
metal ions, and other reactive metabolic byproducts, preventing their interaction with
cellular macromolecules and avoiding excessive lipid and protein oxidation.197,199,202204,227

In vitro assays determined CBD exhibits higher activity than a-tocopherol, the

standard chemical used to determine antioxidant activity.197,199 However, the indirect
modulation of apoptotic and anti-inflammatory signaling pathways is the primary
mechanism of CBD’s antioxidant activity; mediating a response through induction or
suppression of antioxidant and apoptotic signaling pathways, respectively.199,203,204,218,221
CBD can act on transient receptor potential vanilloid receptors (TRPV), peroxisome
proliferator-activated receptors (PPAR-g), 5-hydroxy tryptophan receptors (serotonin),
and adenosine receptors, to modulate inflammatory activity at both the protein
expression and transcription levels.199 In our research, limited CBD treatment activated
Nrf2 signaling as evidenced by the elevated transcription and expression of antioxidant
proteins including Nrf2, HO-1, GSH, SOD.218 We also witnessed elevated protein
expression of Glo-1, Glo-2, and Glo-3 in CBD treated neurons insulted with MG, in a
Nrf2 dependent manner. Our measures of GP activity were enhanced and improved with
CBD treatment. Cerebellar neurons insulted with MG and treated with CBD exhibited
significantly lower levels of MG and ROS, with concomitant elevation in D-lactate, GSH,
and Glo-1 activity.
It was previously believed that flavonoids – and other antioxidant compounds – exhibited
a protective effect through direct neutralization with ROS and inflammatory molecules;
however, the physiological concentration of dietary flavonoids is a far smaller molar
equivalency than ROS produced in the body.18,51,55,76,117,122,136 More recent research
suggests the protective function of flavonoids is indirect, through modulation of
endogenous cellular signaling pathways.1,19,51,75,116,132 Antioxidant compounds – like
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flavonoids and phytocannabinoids – can activate or inhibit cytoprotective and apoptotic
pathways, respectively.11,58,125,132,135,148,150,151,198,218 Upon stimulation via ROS, UV
irradiation, and inflammatory compounds, SAPK/JNK proteins enter the nucleus and act
as transcription factors to induce protein expression. MAPK activation is associated with
caspase activation and cell death, mediated in part through the NF-kB pathway.
60,124,225,228

In a mouse model of aging, hippocampal astrocytes exhibited elevated ROS

production and a concomitant activation of SAPK/JNK.80 MAPK protein p38 is also
involved in Ca2+ mediated apoptosis. Elevated production of ROS causes
phosphorylation of p38, inducing C-AMP response element binding protein (CREB)
inactivation.80 Hypertension and cardiovascular disease also exhibit elevated
inflammatory cytokine signaling and ROS production.84 In a rat model of neural
hypertension, chronic elevated angiotensin elevated NADPH oxidase-produced ROS,
and phosphorylation and activation of SAPK/JNK and p38, resulting in glutaminergic
neuron dysfunction.84 Activation of SAPK/JNK and other MAPKs is exhibited in AD, and
is exacerbated by the presence of Ab.225 Insoluble Ab peptides induce the production of
ROS, and can directly stimulate the activation of SAPK/JNK.225 In a high-glucose model
of neural apoptosis, treatment of cells with p38 and SAPK inhibitors attenuated
apoptosis, and reduced phosphorylation levels of the proteins.225 In our research, we
observed a significant increase in SAPK/JNK phosphorylation upon treatment with MG,
however CBD treatment attenuated SAPK/JNK activation. CBD treatment – with and
without MG – resulted in elevated expression of p38 compared to the controls. In
accordance with this, phosphorylated p38 was significantly decreased in CBD treated
cells, while the MG-treated condition exhibited elevated P-p38. A model of diabetesassociated cognitive decline utilized high glucose conditions to induce markers of OS in
SH-SY5Y cells, which was attenuated with quercetin pretreatment, and Nrf2
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activators.165 It was determined that inhibition of p38 had an influence on Nrf2
phosphorylation and nuclear translocation; preventing activation of p38 through
pretreatment with a p38 inhibitor resulted in decreased presence of AGEs, elevated Nrf2
nuclear translocation and activation.165 In our research we found that MG treatment
elevated expression of P-p38, while treatment with CBD prevented phosphorylation of
p38, even in the presence of MG. In accordance with the previous report, antioxidant
treatment of neurons with CBD elevated Nrf2 levels, while preventing activation of
inflammatory cell signaling pathways.
Imbalanced excitatory and inhibitory neurotransmission is common in neurological
disorders, and contributes to the elevated excitotoxicity and apoptosis present in
neurodegenerative conditions.214 Our research determined limited CBD as possessing
neuroprotective activity in both inhibitory and excitatory neurotransmitter function, as
measured through fluorescence expression of GAD65 and VGLUT. Cerebellar neurons
incubated with CBD exhibited significantly elevated fluorescence expression of GAD65
and VGLUT compared to MG treated controls. CBD also protected neural morphology,
as evidenced by the elevated expression of structural protein MAP2 compared to MG
treated cells.
CBD exhibited remarkable protective effects in vitro, and we desired to replicate this
success in vivo through utilizing model organism C. elegans. For our experiments, we
used several strains of C. elegans possessing genetic mutations in Glo-1 (VC343 and
VH725) and Ab (GRU102) in addition to the WT (N2). The lifespan of C. elegans is
known to be decreased in the presence of oxidative and inflammatory
environments.186,188,229,230 We determined MG treatment to significantly decrease the
lifespan of all strains, compared to untreated controls. Strains VC343 and GRU102
featured increased susceptibility to MG-mediated OS, due to their deficits in endogenous
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antioxidant activity. The Glo-1 overexpressing strain VH725 had a less significant
decrease in lifespan, a consequence of its elevated Glo-1 protein expression. In all
strains, CBD treatment exhibited an extension of lifespan compared to non-treated
controls. CBD and MG cotreatment resulted in a decrease of lifespan compared to the
CBD only and control conditions, however there was a significance in lifespan length
compared to the MG treatment condition. C. elegans are sensitive to oxidative changes
in environments, including elevated H2O2, UV, and temperature.186,188,229,230 To determine
the effect of CBD and MG on environmental stressors in C. elegans, we performed OS
and thermotolerance experiments to investigate survival under extreme conditions. C.
elegans were pretreated with CBD, MG, or a combination and exposed to either H2O2 or
increased temperatures. In the OS tolerance assay, CBD exhibited a protective effect in
all strains exposed to H2O2. As expected, MG pre-treated C. elegans had significantly
decreased survival under oxidative conditions. All combination treatments exhibited in
elevated survival compared to the MG treated condition. The antioxidant compromised
VC343 and GRU102 C. elegans had lower survival percentages compared to the N2
and VH725 strains. CBD treatment also conferred elevated thermotolerance to all
strains, whereas MG treatment reduced survival. All CBD and MG combination
treatments exhibited elevated thermotolerance compared to the MG only condition. CBD
pretreatment conferred protection against elevated levels of OS and temperature.
Although we did not investigate the exact mechanism, CBD is known to activate
antioxidant signaling pathways and induce the expression of cytoprotective proteins
against ROS, and heat-shock proteins to prevent instability and denaturing of
proteins.199-202 To investigate the effect of CBD and MG on production of AD pathology,
we utilized GRU102 C. elegans, which harbor a mutation causing them to overexpress
Ab protein. Because the mutation is tagged with green fluorescent protein (GFP), we
were able to observe expression changes through confocal microscopy. C. elegans
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treated with MG exhibited elevated GFP expression, indicative of increased Ab burden.
CBD treatment significantly decreased Ab expression compared to the non/MG-treated
controls. C. elegans treated with both CBD and MG exhibited a blunting of GFP
expression compared to the MG treated control. In this experiment, results indicated that
CBD is protective against Ab in vivo, possibly through decreased expression or
disrupted fibrillation of Ab. CBD was determined to have a protective effect against MG
in C. elegans strains, regardless of the specific mutations they harbored.
Through measurement of GP function, constituent proteins, and markers of antioxidant
function, we determined CBD to be an effective enhancer of the GP. Under states of
MG-mediated OS, CBD treatment induced an antioxidant response that effectively
attenuated the insult from MG treatment. Our hypothesis that limited CBD enhanced GP
function through modulation of cell signaling pathways was confirmed, and we are the
first to report CBD’s effect on the GP. Our use of both primary neurons and model
organisms provides evidence that CBD is effective in GP enhancement in both in vitro
and in vivo models of MG-mediated OS. We determined CBD’s neuroprotective effect is
mediated through modulation of cellular signaling pathways, and not necessarily directly
involved in MG and ROS neutralization.
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Neurodegenerative conditions exhibit progressive severity in disease pathology, of which
overproduction of ROS and reactive metabolic byproducts is prominently
featured.5,10,12,19 AD and aging features deficits in endogenous responses contribute to
the imbalance of antioxidant and pro-oxidant molecules, resulting in chronic activation of
apoptotic and inflammatory cellular signaling pathways.3,7,8,93 The pathological hallmarks
of AD - Ab, NFT, and loss of brain tissue – can be exacerbated by deficiencies in
endogenous antioxidant systems, in which MG accumulation and elevated ROS
production plays a prominent role.10,13,15,31,92,148 GP dysfunction has a direct role in the
development and progression of AD pathology, and contributes to the cognitive decline
present in the disease.1,3,21,22,26,37,49,64,65,87,128 However, pharmacological modulation of
the GP can attenuate oxidative damage, reduce the pathological burden, and lessen
cognitive deficits associated with aging and AD.1,20,34,37,38,48,49,54,57,58,87,128 Humans have
long utilized naturally-produced plant compounds for therapeutic uses, and the specific
mechanisms of their functions have only recently been elucidated.51,116 The Free Radical
Theory of Aging posits that elevated production of ROS and free radicals is the
contributing factor in human diseases, however the primary mechanism of damage from
free radical production occurs through modulation of cellular signaling pathways.2,18,75,76
It was previously believed that the benefits of flavonoids functioned through direct
binding with ROS, however the concentration of dietary antioxidant molecules would not
be sufficient enough to offset the elevated concentration of ROS found in aging and
AD.9,18,37,51,55,75,76,92,116,121,122,136 Thus the protective effect of flavonoids was determined to
be modulation of antioxidant and apoptotic signaling pathways. 123,127,147,151,152,156,158,161
Our first research project focused on three flavonoid compounds – catechin, morin, and
quercetin – and their effect on the GP.37 We investigated the mechanism of flavonoid
enhancement of GP function through evaluating glyoxalase proteins, markers of
neurotransmitter function, and antioxidant signaling activation.37 We determined the GP-
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enhancing ability of the aforementioned compounds was mediated through activation of
the antioxidant Nrf2 signaling pathway.37 The flavonoid compounds possessed the ability
to attenuate oxidative damage from MG, which is commonly elevated in diseases of
aging and neurodegeneration.37 While all compounds exhibited GP enhancing ability,
our subsequent research project focused on improving morin’s inherent antioxidant
ability through chemical structural additions to the parent compound.128
Metabolic degradation and poor BBB permeability are likely factors in the lack of
success flavonoids have exhibited in in vivo replicates.131 We modified the morin parent
structure - through addition of two bromine molecules, and encapsulation in a polymer
nanoparticle – to produce DBM and MNP and tested efficacy in GP enhancement.128
We repeated previous experimental techniques utilizing DBM and MNP in primary
cerebellar neurons and C. elegans.128 C. elegans are useful organisms in determining
effectiveness of chemical compounds on aging and longevity, due to their genetic
homology with humans and relatively short lifespan.186-188,229-231 We determined the
structural additions to be beneficial in elevating the capacity of the GP compared to the
unmodified morin compound itself.128 DBM and MNP exhibited potent antioxidant and
neuroprotective properties, and attenuated OS-mediated damage through mechanisms
involving induction of Nrf2 signaling and inhibiting NF-kB-mediated apoptosis.128 While
results were successful, the synthesized compounds most promising activity needs to be
tested in higher level organisms, to determine efficacy in preventing premature metabolic
breakdown and BBB permeability. Our final chapter of original research utilized limited
phytocannabinoid CBD to investigate its effect on the GP. While CBD has wellestablished antioxidant and neuroprotective activity in neurodegenerative disorders, we
aimed to elucidate its effect in an MG-mediated model of aging found in AD.154,197,199,201204

We are the first to report results on the effect of CBD in the GP in a neural model of
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MG-mediated OS. Our results showed CBD had a protective effect against MGmediated toxicity in both primary cerebellar neurons and C. elegans strains featuring
overexpression and knockdown of Glo-1 (VH725 and VC343, respectively), and a
mutation in Ab (GRU102). As with our previous research, we intended to elucidate the
cellular signaling pathways involved in CBD’s protective effect. While we found
similarities in the effect of CBD and flavonoids – no doubt due to the structural
similarities shared between the classes of chemical compounds – we also observed
differing modulation of apoptotic and antioxidant signaling pathways. We found that the
antiapoptotic effect of both flavonoids and CBD was mediated through inhibition of NFkB pathway signaling, albeit through different pathway mechanisms. Flavonoids were
found to inhibit activation through modulation of direct NF-kB complex proteins, and
CBD through modulation of stress-activated signaling pathways – SAPK/JNK and p38.
Both classes of compounds induced expression of antioxidant proteins through Nrf2, the
primary transcription factor and activator of the ARE, and thus exhibited similar protein
expression patterns in glyoxalase proteins, HO-1, and GSH. CBD and flavonoids were
found to attenuate the damaging effects of MG accumulation, which occurs in a host of
inflammatory diseases within and outside the CNS, through enhancement of the GP.25,86
Our results show that secondary plant metabolites of different structural classifications
can increase the capacity of the GP and allow for the retention of neurotransmitter
activity and neuron morphology even in the presence of a cytotoxic and highly
inflammatory cellular environment. These findings necessitate further research in higher
organisms to fully elucidate the mechanisms of protection the GP, and how it can be
best manipulated for therapeutic effects in aging and AD.
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